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Abstract Acquired therapeutic resistance by tumors is a substantial impediment to reducing the
morbidity and mortality that are attributable to human malignancies. The mechanisms responsible
for the dramatic shift between chemosensitivity and chemoresistance in colorectal carcinoma have
not been defined. Here, we report that LRP16 selectively interacts and activates double-stranded
RNA-dependent kinase (PKR), and also acts as scaffolds to assist the formation of a ternary
complex of PKR and IKKb, prolonging the polymers of ADP-ribose (PAR)-dependent nuclear factor
kappa B (NF-kB) transactivation caused by DNA-damaging agents and confers acquired
chemoresistance. We also identified a small molecule, MRS2578, which strikingly abrogated the
binding of LRP16 to PKR and IKKb, converting LRP16 into a death molecule and forestalling colon
tumorigenesis. Inclusion of MRS2578 with etoposide, versus each drug alone, exhibited synergistic
antitumor cytotoxicity in xenografts. Our combinatorial approach introduces a strategy to enhance
the efficacy of genotoxicity therapies for the treatment of tumors.
DOI: 10.7554/eLife.27301.001
Introduction
Death in patients afflicted with cancer is mainly due to uncontrollable recurrence of the primary
tumor following failure of current therapies. Colorectal cancer (CRC) is one such cancer type wherein
aggressive treatment strategies including surgery, ionizing radiation (IR), and chemotherapy provide
only palliation (Benson et al., 2004; de Gramont et al., 2000). The most important factor limiting
the success of systemic anticancer therapy in achieving cure or prolonged overall survival has been
drug resistance, either because the initial tumor fails to respond to therapy or because it acquires
resistance during relapse (Holohan et al., 2013; Kuczynski et al., 2013). The anticancer activity of
most chemotherapy drugs relies on the induction of DNA damage in rapidly cycling tumor cells with
inadequate DNA repair. However, damage induced by drugs is not invariably lethal but instead
actively triggers damage responses, and it is these responses that determine the eventual fate of the
cell (Johnstone et al., 2002). Given the adaptability of tumor cells, it seems likely that drug resis-
tance will continue to be an important clinical problem, even in the age of targeted therapeutics and
tailored treatment regimes (Lowe et al., 2004). Thus, novel therapeutic strategies that circumvent
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the mechanisms of resistance are urgently required to improve the survivorship of cancer patients.
Our understanding of the mechanisms that protect tumor cells from the cytotoxicity induced by
drugs must be improved.
The nuclear factor kappa B (NF-kB) signaling pathway, which is activated by many stimuli, is a cru-
cial transcription factor in a variety of pathophysiological conditions (Harhaj and Dixit, 2012;
Hayden and Ghosh, 2008; Smale, 2011; Wan and Lenardo, 2010). NF-kB responds to genotoxic
threats via the activation of the inhibitor of NF-kB kinase (IKK) and NF-kB liberation from IkB pro-
teins, similar to the canonical pathway activated by external stimuli (Janssens et al., 2005; Per-
kins, 2007; Wu et al., 2006). The NF-kB signaling pathway has emerged as an important mediator
for cellular responses to DNA damage, in particular NF-kB-conferred anti-apoptotic transcription
facilitates the escape of cells from the lethal effects of DNA damage (Janssens et al., 2005; Per-
kins, 2007; Wu et al., 2006), and initiates cell cycle checkpoint control to promote cellular recovery
from damage (McCool and Miyamoto, 2012; Miyamoto, 2011), thereby contributing to acquired
resistance to DNA-damaging cytotoxic therapies. Besides NEMO (also named IKKg ) and ataxia telan-
giectasia mutated (ATM), two known crucial regulators of the genotoxic stress-activated NF-kB sig-
naling pathway (Miyamoto, 2011), poly(ADP-ribose) polymerase 1 (PARP1) was recently revealed to
be indispensable for the signaling cascade that links nuclear DNA damage recognition to cyto-
plasmic IKK activation (Stilmann et al., 2009). Sequential posttranslational modifications (PTMs),
including phosphorylation, ubiquitination and SUMOylation, of these signaling regulators are critical
for NF-kB activation following DNA damage (Huang et al., 2003; Mabb et al., 2006; Wu et al.,
2006). In this regard, PARP1 is an abundant nuclear protein that senses and contributes to the repair
of DNA single-strand breaks (SSBs) and of DNA double-strand breaks (DSBs), working by catalyzing
poly(ADP-ribosyl)ation (PARylation) of itself, histones, and other target proteins (Gibson and Kraus,
2012). In particular, PARP1-catalyzed PARylation has emerged as a vital means for the rapid assem-
bly of signaling complexes that are critical for DNA damage-initiated NF-kB activation (Mabb et al.,
2006; Stilmann et al., 2009). However, the cooperative function of NF-kB with other key stress ele-
ments in cellular resistance to DNA-damaging therapies remains to be clarified. How DSBs trigger
the activities of such a large number of factors with such precise spatiotemporal coordination also
remains unclear. Leukemia-Related Protein 16 (LRP16), a member of the macro domain family, was
identified as a PAR-binding protein in genotoxic threat-treated cells and a putative substrate of
eLife digest Most chemotherapy drugs kill cancer cells by damaging their DNA. The cells have
systems to combat this damage and help them to survive, and in some cells these systems work
effectively enough to make the cancer effectively resistant to the treatment. For example, a protein
called NF-kB can turn on various genes that help to repair damaged DNA. However, DNA is
contained the cell nucleus, whereas the inactive form of NF-kB is found outside the cell nucleus. So
how does the damaged DNA communicate with – and activate – NF-kB?
Previous research had found that another protein called LRP16, which resides in the cell nucleus,
plays a crucial role in the repair process that NF-kB is involved in. Li, Wu, An et al. have now studied
bowel cancer cells taken from human tissue samples and found that the cancerous cells contained
higher levels of LRP16 than cells from the surrounding tissue. Patients with cancers containing very
high levels of LRP16 were more severely affected by cancer. Further investigation revealed that
when DNA is damaged, LRP16 moves out of the cell nucleus and stabilises how NF-kB interacts with
two other proteins; this stabilisation activates NF-kB. LRP16 therefore appears to regulate the signal
that travels out of the nucleus from the damaged DNA to activate NF-kB.
Further experiments showed that anti-cancer treatments worked best on cancer cells that lacked
LRP16. Thus it appears that LRP16 helps cancer cells to respond to and resist the DNA damage
caused by chemotherapy. Li, Wu, An et al. went on to identify a drug that prevented the activation
of NF-kB by blocking the effects of LRP16. Using this drug alongside chemotherapy drugs made the
cells more likely to self-destruct. More work is now needed to develop therapies based on the newly
identified drug and to establish how DNA damage activates LRP16.
DOI: 10.7554/eLife.27301.002
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PARP1, which suggests that LRP16 could be an important molecule in the cellular response to DNA
damage (Han et al., 2011; Timinszky et al., 2009). We have previously established a critical role for
LRP16 in DSB-induced activation of the NF-kB signal transduction cascade, which counteracts apo-
ptosis and allows cells to escape the lethal effects of DNA damage (Wu et al., 2015). Mechanisti-
cally, LRP16 facilitates the lesion-specific recruitment of PARP-1 and NEMO through its constitutive
interactions with these two proteins, and then ultimately facilitates the concomitant recruitment of
ATM and protein inhibitor of activated STAT Y (PIASy) to NEMO to ensure the activation of NF-kB
after the induction of DSBs (Wu et al., 2015). Although these studies have considerably advanced
our understanding of the cellular response to DNA damage, the genotoxic stress-initiated nucleo-
plasmic NF-kB signaling pathway remains poorly understood, in particular, the early signaling net-
works linking DNA lesion recognition in the nucleus to subsequent activation of IKK and liberation of
NF-kB in the cytoplasm. The double-stranded-RNA (dsRNA)-activated protein kinase PKR, a ubiqui-
tously expressed serine/threonine kinase, has been implicated in the regulation or modulation of cell
growth through multiple signaling pathways and has also been described as a signal integrator in
the translational and transcriptional control pathways (Bennett et al., 2006; Dar et al., 2005;
Donzé et al., 2004; Liu et al., 2013). In addition to its functional regulatory function, PKR has a role
in signal transduction and transcriptional control through the IkB/NF-kB pathways (Gil et al., 2000,
2004). PKR has also been implicated in different stress-induced signaling pathways including dsRNA
signaling to NF-kB activation, although the precise function of PKR in these signaling pathways
remains controversial. Not only is PKR an effector molecule in the cellular response to dsRNA, but it
also integrates signals in response to the activation of Toll-like receptors, growth factors, and diverse
cellular stresses (Hsu et al., 2004; Nakamura et al., 2010). PKR is involved in multiple pro- and anti-
apoptotic pathways in normal and cancer cells. Investigators have shown that PKR specifically inter-
acts with STATs, FADD, and IKK (Williams, 2001), and researchers have also described a novel role
for PKR as a mediator of IR resistance, modulated partly by the protective effects of NF-kB activation
(von Holzen et al., 2007). Although some models have been proposed, the precise molecular mech-
anism by which PKR activates IKK/NF-kB pathways remains to be determined. Moreover, PKR is also
involved in many cellular pathways, exerting various functions on cell growth and tumorigenesis
(Marchal et al., 2014). However, the exact role of PKR in cancer biology remains controversial. Che-
motherapeutic drugs such as doxorubicin, etoposide, and 5-fluorouracil are able to induce and acti-
vate PKR protein, triggering apoptosis (Garcı́a et al., 2011; Peidis et al., 2011; Yoon et al., 2009).
Conversely, PKR has been suggested to be involved in the neoplastic process of the proliferative
transcription factor NF-kB (Delgado André and De Lucca, 2007). Curiously, different expression
patterns of PKR/eIF2a/NF-kB activity, even in the same type of cancer, such as different cholangio-
carcinoma cell lines, point to the complexity of the role of PKR in cancer (Kunkeaw et al., 2013).
In the current study, we report how DNA-damage-induced nuclear events are linked to the activa-
tion of cytoplasmic IKK kinase, thereby activating NF-kB. LRP16 selectively interacts and activates
PKR, and it also acts as a scaffold to assist the formation of a ternary complex of PKR and IKKb, pro-
longing PAR-dependent NF-kB transactivation caused by genotoxic threats. We also discovered a
small molecule MRS2578 that could profoundly abolish these interactions, converting LRP16 into a
death molecule and forestalling colon tumorigenesis and acquired resistance to DNA-damaging
therapies driven by the oncogenes of the NF-kB pathway. This study takes CRC as a model to under-
stand mechanisms that account for a limited response of genotoxic therapies in solid tumors and to
seek combination solutions. Inclusion of etoposide plus MRS2578, versus each drug alone, exhibits
synergistic tumor cytotoxicity both ex vivo and in vivo. Our combinatorial approach introduces a
strategy to enhance the efficacy of DNA-damaging cytotoxic therapies for the treatment of cancer.
Thus, targeting the biological function of LRP16 will provide the proof of principle for two under-
studied concepts in cancer therapy: (1) blocking subsignals, rather than total signals, as a means of
impeding oncogenic NF-kB signaling and (2) targeting regulatory protein–protein interactions as a
way to produce effective antitumor agents and to sensitize tumor cells to DNA-damaging cytotoxic
therapies.
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Results
Massive LRP16 expression predicts a poor prognosis in human CRC
patients
To clarify the clinicopathological relevance of LRP16 in patients with CRC, we used immunohis-
tochemistry (IHC) to examine the LRP16 protein levels in a human tissue array containing 202 CRC
clinical specimens with paired adjacent normal colon tissues from patients with CRC. An analysis
using the Image-Pro Plus software showed that the level of LRP16 expression was significantly higher
in the CRC tissue samples than the adjacent normal tissues (Figure 1A–B). LRP16 was highly ele-
vated in primary CRC tumors compared with their adjacent normal tissues as determined by reverse
transcription polymerase chain reaction (RT-PCR) and Western blot analysis (Figure 1—figure sup-
plement 1A). These CRC samples were staged according to the system developed by the American
Joint Committee on Cancer (AJCC), also known as the Tumor-Node-Metastasis (TNM) system. Nota-
bly, we found that the level of LRP16 expression positively correlated with the histological grades of
the tumors and was also strongly associated with a higher tumor stage (Figure 1C–D and Figure 1—
figure supplement 1A and Figure 1—source data 1), suggesting that the level of LRP16 expression
is progressively elevated during the progression of the patients with CRC. A Kaplan–Meier survival
analysis of the expression of LRP16 and the clinical behavior of CRC further showed that a low level
of LRP16 was associated with better overall survival (OS) in CRC patients (p=0.0224) (Figure 1E). In
this context, LRP16 expression was an independent prognostic factor, with a hazard ratio (HR) of
0.58 (95% confidence interval [CI] 0.36–0.90) in a multivariate analysis (tumor grades HR 0.46 [95%
CI 0.26–0.82]; tumor stages HR 0.44 [95% CI 0.21–0.93]), which is similar to our previous findings
(Xi et al., 2010). Interrogation of the most comprehensive public database, The Cancer Genome
Atlas (TCGA) (Cancer Genome Atlas Network, 2012), also supported the notion that the expres-
sion of LRP16 transcripts is profoundly elevated in CRC. Interestingly, this database also showed
that when CRC samples were further stratified according to their tumor stage, the level of LRP16
expression also positively correlated with the clinical tumor stages (TNM stage) of these patients
with CRC (Figure 1F–G). Further analysis of our data and the TCGA database showed that the level
of LRP16 expression also positively correlated with the histological grades of these CRC patients
and that, remarkably, high levels of LRP16 expression in CRC strongly correlated with lymph-node
positivity and metastasis in the cohort of patients with CRC (Figure 1H–I and Figure 1—source
data 1).
NF-kB is constitutively activated in many malignancies, including CRC (Sakamoto et al., 2009),
but the molecular mechanism underlying the constitutive activation of NF-kB in tumors remains to
be defined. NF-kB activation was defined as the detection of p65 nuclear staining in over 50% of the
tumor cells in the CRC tissues. Constitutive activation of NF-kB was observed in 28.7% (58 of 202) of
the cohort of patients with CRC (Figure 1J). The total p65 levels slightly differed among the CRC
samples, but they were significantly elevated in CRC samples compared with the adjacent normal tis-
sues (Figure 1J), and also positively correlated with the histological grades of the tumors (Figure 1—
figure supplement 1B). An analysis of consecutive tissue sections showed that the level of LRP16
expression positively correlated with the level of p65 expression (Figure 1K). The correlation
between LRP16 and p65 was further confirmed in a larger scale array of 202 samples. Specifically,
approximately 66% of the samples with high LRP16 expression displayed high p65 expression,
whereas approximately 68% of the low LRP16 samples displayed low p65 expression (Figure 1L).
Similar to the expression of LRP16, the phosphorylation of p65 (phospho-p65) at Ser536, which rep-
resents the activated form of NF-kB, was significantly higher in CRC tissues. Analysis of phospho-
p65 protein expression by Western blot analysis mirrored that of LRP16, with the highest expression
observed in CRC samples. Most importantly, high expression levles of phospho-p65 correlated posi-
tively with high expression levels of LRP16 in CRC clinical specimens (Figure 1—figure supplement
1B). Informatively, XIAP (a target of NF-kB) expression was significantly elevated in all 202 CRC tis-
sues compared with the adjacent normal tissues (Figure 1—figure supplement 1C). However, we
did not observe a significant correlation between LRP16 and XIAP expression in these CRC samples
(Figure 1—figure supplement 1D). Moreover, analysis of the TCGA CRC RNA-seq dataset revealed
that LRP16 expression was also not significantly correlated with that of BCL2L1 (anti-apoptotic tran-
scriptional target of NF-kB), but it was inversely correlated to that of XIAP (Figure 1—figure supple-
ment 1D). A different trend in the relevance of LRP16 and XIAP expression in our and the TCGA
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Figure 1. LRP16 is progressively elevated expression during progression of CRC. (A) Representative images of tumors and matched adjacent tissues
from a tissue array containing 202 CRC samples paired with adjacent normal colon tissues, which were immunohistochemically (IHC) stained for LRP16
expression. The outlined areas in the left images are magnified on the right. Scale bars, 50 mm. (B) LRP16 expression scores by IHC shown as scatter dot
plots. We compared the CRC tissues with the matched adjacent normal colon tissues using the Wilcoxon matched pairs test (n = 202). Error bars
represented the mean ± SD. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. (C–D) Analysis of LRP16 expression levels in CRC samples based on the
indicated stratification (T stages and tumor stages). Error bars represented the mean ± SD. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. (E) Kaplan–
Meier plot of the overall survival (OS) of 202 patients with CRC (two groups stratified by LRP16 expression level: low LRP16 [0 and 1], N = 87; high LRP16
[2 and 3], N = 115). A log-rank test was used to compare the differences between two groups. (F–I) Raw data were exported from The Cancer Genome
Atlas (TCGA) CRC database. Whisker plots of the expression of LRP16 in CRC samples based on the indicated stratification, T stages (F), tumor stages
(G), lymph-node metastasis (H), distant metastasis (I). Data presented as the log2 median-centered ratio expression. Unpaired Mann–Whitney test was
used to evaluate statistical significance. Error bars represented the mean ± SD. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. (J) Representative images
of CRC tissue samples and matched adjacent tissues from a tissue array containing 202 CRC samples paired with adjacent normal colon tissues, IHC
stained for p65 expression. The outlined areas in the left images are magnified on the right. Scale bars, 50 mm. p65 expression scores are shown as
scatter dot plots. We compared the CRC tissues with the matched adjacent normal colon tissues with the Wilcoxon matched pairs test (N = 202). Error
Figure 1 continued on next page
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cohorts of patients with CRC might be attributable to the dynamic expression patterns of NF-kB tar-
get genes, which did not follow a standardized protocol and differed in the number of CRC samples
analyzed and in the patient inclusion criteria, making it difficult to compare results between groups.
Taken together, these results provide overwhelming clinical evidence that LRP16 is overexpressed in
human CRC samples compared with adjacent normal samples, and also confirms the critical role of
LRP16 in promoting CRC tumorigenesis.
LRP16 attenuates the cytotoxic and cytostatic effects of DNA-
damaging therapeutics
To explore the biological role of LRP16 in CRC, we screened a panel of CRC cell lines for their
endogenous LRP16 levels (Figure 2A). We also observed that the level of phospho-p65 expression
was positively associated with the level of LRP16 expression (Figure 2—figure supplement 1A).
Next, we investigated the cytotoxic and cytostatic effects of chemotherapeutic drugs on CRC cell
lines in culture models. In these cells, we compared the cytotoxic and cytostatic effects of etoposide
to those of 5-fluorouracil and oxaliplatin, as reflected by their half-maximal growth inhibitory concen-
trations (IC50). The results indicated that CRC cell lines (i.e. LS180, HCT116, and RKO) expressing rel-
atively higher levels of endogenous LRP16 were less sensitive to etoposide. In contrast, CRC cell
lines expressing relatively lower or undetectable levels of endogenous LRP16 (i.e. SW480, CaCO2,
and LoVo) were more sensitive to etoposide (Figure 2—figure supplement 1B). Based on our find-
ings, it is reasonable to speculate that the molecular mechanisms underlying the therapeutic
response difference to the cytotoxic and cytostatic effects of etoposide might be dependent on the
different levels of LRP16 expression in CRC cell lines. We further examined whether expression of
exogenous LRP16 could restore the resistance of CRC cell lines to a basic low level of LRP16 expres-
sion in response to chemotherapeutic drugs. As expected, the forced overexpression of LRP16 in
SW480 cells with a basic low level of LRP16 rendered tumor cells more resistant to etoposide than
to the other two drugs, as evidenced by increased cell viability and clonogenicity (Figure 2B and
Figure 2—figure supplement 2A–B). Increasing the expression of LRP16 substantially rescued eto-
poside-induced apoptosis, as evidenced by reduced caspase three cleavage (Figure 2C). However,
no significant protective effects were observed on the invasive and metastatic capacities of the CRC
cell line ex vivo (Figure 2—figure supplement 2C).
Next, we assessed how LRP16-mediated anti-apoptotic signaling accounted for the limited
response to etoposide. A conceivable possibility is that NF-kB activation caused by LRP16 in
response to etoposide could account for this protective effect (Figure 2D). We found that elevated
phospho-p65 levels, which were associated with substantially enhanced NF-kB transcriptional activ-
ity, occurred in the most etoposide non-responsive cell lines. Conversely, in some etoposide-respon-
sive cells, upregulation of the phospho-p65 level or NF-kB transcriptional activity did not remarkably
occur (Figure 2—figure supplement 1B and Figure 2—figure supplement 2D). The Western blot
results also showed that with a gradually increase in LRP16 expression significantly increased the
phosphorylated forms, but not the total forms, of the upstream regulators of the NF-kB pathway,
IKKa and IKKb, and also increased the levels of phospho-p65 (Figure 2E), compared with those in
controls. Similar results in clonogenicity experiments demonstrated that the gradual re-expression of
Figure 1 continued
bars represented the mean ± SD. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. (K) Representative images of two serial sections from the same tissue
samples IHC stained for LRP16 and p65. Scale bars, 50 mm. (L) Positive correlation between LRP16 and p65 expression levels. The 202 samples were
classified into two groups (low LRP16, N = 87; high LRP16, N = 115) based on the LRP16 level relative to the score for the whole cohort. p<0.01,
calculated with both the c2 and Mann–Whitney tests. Pearson correlation between LRP16 and p65 expression levels (N = 102; p<0.0001; R2 = 0.09732).
DOI: 10.7554/eLife.27301.003
The following source data and figure supplement are available for figure 1:
Source data 1. LRP16 expression in tumor-adjacent tissues of the colorectal carcinoma (CRC) patient subgroups according to clinical pathological
parameters.
DOI: 10.7554/eLife.27301.004
Figure supplement 1. LRP16 is significantly elevated and positively correlates with constitutive NF-kB activation in human CRC samples.
DOI: 10.7554/eLife.27301.005
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Figure 2. LRP16 mediates acquired resistance to etoposide in CRCs. (A) Expression levels of LRP16 were analyzed in 11 CRC cell lines with Western
blotting and RT–qPCR. (B) Cell growth assay. SW480 cells were transfected with the control vector or an LRP16-expressing plasmid for 48 hr, and then
treated with etoposide, 5-fluorouracil, or oxaliplatin for a further 72 hr. Cell viability was determined with a CCK-8 assay. (C) SW480 cells transfected
with an LRP16-expressing plasmid or the control vector were treated for 36 hr with the indicated concentrations of etoposide and/or BAY 11–7082. Cell
lysates were separated with SDS-PAGE and analyzed with Western blotting using the indicated antibody. b-Actin was used as the loading control. (D)
SW480 cells transfected with an LRP16-expressing plasmid or the control vector were treated with etoposide (50 mM), 5-fluorouracil (100 mM), or
oxaliplatin (2 mg/ml) for 3 hr, and the cell lysates were analyzed with Western blotting using the indicated antibodies. (E) SW480 cells transfected with
increasing doses of an LRP16-expressing plasmid or the control vector were treated with etoposide (50 mM), and then immunoblotted with the
indicated antibodies. (F) SW480 cells transfected with an LRP16-expressing plasmid or the control vector were pretreated with or without BAY 11–7082
and then treated with etoposide for indicated concentrations, and subjected to a cell viability analysis. (G) SW480 cells transfected with the indicated
plasmids and treated with etoposide for indicated concentrations, and subjected to a cell viability analysis. (H) SW620 cells were transfected with
control or LRP16-directed shRNAs, and the resulting stable cells were treated with etoposide and subjected to a cell viability analysis. Data are
representative of at least three independent experiments.
DOI: 10.7554/eLife.27301.006
Figure 2 continued on next page
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exogenous LRP16 in SW480 cells restored their resistance to etoposide (Figure 2—figure supple-
ment 3A).
Hence, we wondered whether NF-kB activation enhanced by LRP16 potentially contribute to the
limited response to etoposide. To achieve this goal, we assessed the impact of the NF-kB inhibitor,
BAY 11–7082, and the IkBa super-repressor, IkBaSR, a dominant-negative mutant of IkBa
(Wu et al., 2015), which blocks the effects of NF-kB activation on the viability and clonogenicity of
CRC cells. Blocking NF-kB activation with either BAY 11–7082 or IkBaSR in SW480 cells exogenously
expressing LRP16 or the vector control profoundly reduced their viability and clonogenicity
(Figure 2F–G and Figure 2—figure supplement 3B). These results suggest that LRP16 confers DNA
damage-triggered NF-kB-mediated expression of anti-apoptotic signaling molecules and is involved
in restraining the response to DNA-damaging cytotoxic therapies in CRC cells.
To determine whether LRP16 is the relevant target at the cellular level and whether cell killing is
truly dependent on this particular mechanism, LRP16 was specifically knocked down using two differ-
ent LRP16 small hairpin RNAs (shRNAs, siRNA_374 and _668), as described previously (Wu et al.,
2015). Cells stably expressing LRP16 siRNA_374, siRNA_668, or control_siRNA were treated with
etoposide for 72 hr. Notably, depletion of endogenous LRP16 resulted in significantly reduced cell
viability and clonogenicity and profoundly enhanced the sensitivity of cells to etoposide (Figure 2H
and Figure 2—figure supplement 3C). Beyond its indispensable role in DNA repair (Gibson and
Kraus, 2012), emerging evidence reveals that PARP1-mediated PARylation is one of the most crucial
PTMs orchestrating DNA-damage-initiated NF-kB signaling (Stilmann et al., 2009). The high affinity
of LRP16 for PAR led us to further ascertain whether LRP16 could facilitate PAR-dependent NF-kB
signaling/transactivation of anti-apoptotic genes to counter intrinsic DNA damage in CRC cells and
to protect against cell death induced by genotoxic agents. Of note, ectopic expression of LRP16
mutants (D160A or I161A), which was sufficient to significantly reduce its affinity for PAR, but not
LRP16 wild-type (WT), in SW480 cells, dramatically sensitized the tumor cells to genotoxic stress-
induced apoptosis, as conveyed by reduced cell viability and clonogenicity, in line with the indispen-
sible role of the affinity of LRP16 for PAR in NF-kB activation and anti-apoptotic transcription (Fig-
ure 2—figure supplement 3D). Consistently, PARP inhibition by PJ-34 or 3-AB treatment also
significantly reduced CRC cells survival and dramatically sensitized cancer cells to etoposide-induced
cell death, as evidenced by the reduced cell viability and clonogenicity, in LRP16-upregulated
SW480 cells (Figure 2—figure supplement 3D). Taken together, these data suggest that LRP16
plays a critical role in DNA-damage-initiated and PAR-dependent NF-kB transactivation, which could
account for the limited or lack of response to the cytotoxic and cytostatic effects of etoposide and
protection against cell death induced by genotoxic agents.
LRP16 sustains NF-kB activation induced by genotoxic threats
To further assess whether LRP16 is an essential component of NF-kB signaling, we used an immuno-
blotting assay to evaluate genotoxicity-induced NF-kB transcriptional activity. The results indicated
that the re-expression of LRP16 in cells exposed to etoposide profoundly increased the phosphory-
lated forms, but not the total forms, of the upstream regulators of the NF-kB pathway, IKKa, IKKb
and IkBa, in a dose- and time-dependent manner (Figure 3A). Consistent with this phenomenon,
exposure to IR, together with exogenous LRP16 expression, also largely prolonged the IR-stimulated
activation of NF-kB compared with that in cells transfected with control vector (Figure 3B). Similar
results were repeated in another CRC cell line, LoVo cells (Figure 3—figure supplement 1A–B).
Moreover, compared with control cells, etoposide treatment triggered the marked nuclear
Figure 2 continued
The following figure supplements are available for figure 2:
Figure supplement 1. The cytotoxic and cytostatic effects of chemotherapeutic drugs on CRC cell lines.
DOI: 10.7554/eLife.27301.007
Figure supplement 2. LRP16 plays a critical protective role for the survival of CRC cells.
DOI: 10.7554/eLife.27301.008
Figure supplement 3. The protective roles of LRP16 for CRC cell survival rely on PAR-dependent NF-kB activation in response to DNA damage.
DOI: 10.7554/eLife.27301.009
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Figure 3. LRP16 is required for genotoxicity-induced NF-kB activation. (A) Whole cell lysates from cells transfected with an LRP16-expressing plasmid or
the control vector were treated with the indicated concentrations of etoposide for 2 hr or with 50 mM etoposide for the indicated periods, and then
immunoblotted with the indicated antibody. b-Actin was used as the loading control. (B) SW480 cells transfected with an LRP16-expressing plasmid or
the control vector were treated with IR for the indicated dose. The cell lysates were then separated with SDS-PAGE and analyzed with Western blotting
using the indicated antibody. (C) Whole-cell lysates from SW620 cells transfected with the indicated siRNAs and treated with the indicated
concentrations of etoposide for 2 hr or with 50 mM etoposide for the indicated periods were immunoblotted with the indicated antibody. b-Actin was
used as the loading control. (D) SW620 cells were transfected with the indicated siRNAs and exposed to IR for the indicated periods. Their lysates were
separated with SDS-PAGE and analyzed with Western blotting using the indicated antibody. (E) SW620 cells were cotransfected with the indicated
siRNAs and/or the LRP16-expressing vector that contained silent mutations in the sequences that targeted by the LRP16 siRNAs, and were then treated
with 50 mM etoposide for the indicated periods. The cell lysates were immunoblotted using the indicated antibody. (F) Whole cell lysates of cells
transfected with the control vector or vectors expressing LRP16 or the LRP16 mutants (LRP16_D160A, LRP16_I161A) and treated with the indicated
concentrations of etoposide for 2 hr or with 50 mM etoposide for the indicated periods were immunoblotted with the indicated antibody. b-Actin was
used as the loading control. One representative experiment of three was shown.
DOI: 10.7554/eLife.27301.010
The following figure supplements are available for figure 3:
Figure supplement 1. LRP16 executes an essential function in the nuclear-initiated NF-kB signaling in response to DNA damage.
Figure 3 continued on next page
Li et al. eLife 2017;6:e27301. DOI: 10.7554/eLife.27301 9 of 34
Research article Cancer Biology Cell Biology
translocation of NF-kB/p65 in SW480 cells exogenously expressing LRP16 (Figure 3—figure supple-
ment 1C). Conversely, LRP16 deficiency introduced by its siRNAs in cells exposed to etoposide
reduced the phosphorylated forms, but not the total forms, of IKKa, IKKb, and IkBa, in a dose- and
time-dependent manner (Figure 3C). Consistent with these data, IR triggered the phosphorylation
of IKKa, IKKb, and p65, and IkBa was substantially reduced in SW620 cells expressing LRP16-specific
siRNAs compared with those transfected with scrambled nonspecific siRNAs (Figure 3D). Moreover,
the nuclear accumulation of NF-kB/p65 was also substantially reduced in the LRP16-specific siRNAs-
transfected cell lysates compared with that in the controls (Figure 3—figure supplement 1D). Taken
together, these results support the critical function of LRP16 in controlling the DNA damage-stimu-
lated activation of NF-kB.
To control for potential off-target effects of the LRP16 siRNA and to confirm that LRP16 defi-
ciency alone impairs the genotoxicity-induced activation of NF-kB, we generated an LRP16-express-
ing vector that contained silent mutations in the sequences that were targeted by the LRP16-
directed siRNAs. Our results showed that the etoposide-triggered phosphorylation of IKKa, IKKb,
p65, and IkBa was substantially reduced in the LRP16 siRNA_374-transfected cell lysates. Con-
versely, exogenous expression of LRP16 with a silent mutation at the shRNA target site rescued this
effect (Figure 3E). However, our results also indicated that, compared with the control, the exoge-
nous expression of LRP16 had almost no effect on the activation of NF-kB1 (noncanonical NF-kB sig-
naling pathway) induced by etoposide (Figure 3—figure supplement 2A). These data suggest that
LRP16 is a key regulator of the activating phosphorylation of the activation loops of IKKs and hence
of IKK function in the physiological context. Exactly how any specific signaling pathway targets the
IKK complex remains contentious. TAK1 is considered to be the immediate upstream activator of
IKK and an essential component of both the nuclear and receptor-mediated activation of NF-kB,
phosphorylating the activation loops of the IKKs (Perkins, 2007). Next, we asked whether LRP16
regulates the kinase activity of TAK1 upon DNA damage and mediates activation of the IKK com-
plex. Unexpectedly, the exogenous expression of LRP16 in SW480 cells did not induce significant
phosphorylation of TAK1 compared with that in the control (Figure 3—figure supplement 2B), rais-
ing the additional possibility that other upstream kinases could contribute to the activation of IKK
mediated by LRP16 within the context of etoposide-induced NF-kB signal transduction.
Next, we sought to evaluate whether the function of LRP16 in genotoxic stresses-induced NF-kB
activation was dependent on its PAR binding ability. Ectopic expression of LRP16 WT, but not its
mutants (D160A or I161A), which were sufficient to significantly reduce its affinity to PAR (Wu et al.,
2015), significantly enhanced NF-kB activation after etoposide treatment, as conveyed by the phos-
phorylated forms of IKKa and IKKb, p65, and IkBa (Figure 3F). A luciferase assay using an NF-kB-
responsive element demonstrated that NF-kB transcriptional activity is altered in response to the
modulation of LRP16 upon stimulation of DNA damage. Ectopic of LRP16 remarkably enhanced the
levels of NF-kB-dependent luciferase reporter gene activity in both SW480 and LoVo cells following
either etoposide or IR treatment (Figure 3—figure supplement 3A). Conversely, LRP16 deficiency
introduced by two siRNAs in both HCT116 and SW620 cells considerably diminished the NF-kB tran-
scriptional activity in response to etoposide or IR (Figure 3—figure supplement 3B). Of note,
ectopic expression of LRP16 WT, but not its mutants (D160A or I161A) dramatically enhanced the
NF-kB transcriptional activity in response to etoposide or IR (Figure 3—figure supplement 3A),
thus supporting the critical function of LRP16 in controlling DNA damage-initiated and PAR-depen-
dent NF-kB signaling activation.
Figure 3 continued
DOI: 10.7554/eLife.27301.011
Figure supplement 2. LRP16 is required for NF-kB transactivation in response to genotoxic stress.
DOI: 10.7554/eLife.27301.012
Figure supplement 3. LRP16 is not critical for NF-kB1 and TAK1 activation during the cellular response to gentoxic stress.
DOI: 10.7554/eLife.27301.013
Figure supplement 4. Ectopic of LRP16 augments DNA-damage-triggered NF-kB-mediated expression of anti-apoptotic molecules.
DOI: 10.7554/eLife.27301.014
Li et al. eLife 2017;6:e27301. DOI: 10.7554/eLife.27301 10 of 34
Research article Cancer Biology Cell Biology
NF-kB-mediated transcription of a panel of anti-apoptotic molecules is an important factor for
cell fate determination after DNA damage. To further gain support for the notion that LRP16 regu-
lates distinct target genes of NF-kB, an exploratory microarray analysis was performed. The results
indicate that cells exogenously expressing LRP16 in response to etoposide develop alterations of
the global transcription profile (Figure 3—figure supplement 4A). Further pathway analysis has
revealed several pathways that are highly affected by LRP16, including protein-K63-linked ubiquitina-
tion, IkB phosphorylation, and the DNA damage response (Figure 3—figure supplement 4B). To
further confirm that LRP16 is involved in the expression of NF-kB-dependent genes, human NF-kB
signaling pathway PCR array was used. The results indicate that after exposure to etoposide, the
expression of apoptosis-related genes was markedly downregulated, whereas the expression of anti-
apoptosis-related genes was strikingly increased in cells with exogenously expression of LRP16, com-
pared with the control cells (Figure 3—figure supplement 4C). These results suggest that LRP16 is
functionally involved in the NF-kB-dependent gene expression induced by etoposide stimulation
and might account for the compromised therapeutic efficacy of etoposide.
LRP16 physically interacts with PKR and IKKb in the cytoplasm
We hypothesized that a unique LRP16-containing protein complex forms under genotoxic threat
conditions and that the complex component(s) affect NF-kB activity. Thus, LRP16 interactors were
purified by immunoaffinity purification (Nakatani and Ogryzko, 2003), and we identified the LRP16-
associated proteins by exhaustive rounds of ‘shotgun’ liquid chromatography and high-throughput
mass spectrometry (LC–MS/MS) (Figure 4A). An in-depth bioinformatics analysis of the LC–MS/MS
data indicated that PKR with the matching peptide potentially interacted with LRP16. Importantly,
the interaction of endogenous LRP16 with PKR protein was confirmed by coimmunoprecipitation
(co-IP) in SW480 cells after etoposide treatment (Figure 4B). To exclude the possibility that the
interaction between LRP16 and the PKR protein was indirect and mediated by DNA or chromatin,
ethidium bromide (EB) was added to the cell lysates during co-IP. As expected, ethidium bromide
did not markedly impair the etoposide-induced interaction between LRP16 and PKR, suggesting
that this interaction was also DNA-independent (Figure 4C).
To identify the region within PKR responsible for its interaction with LRP16, we generated several
PKR deletions and mutant constructs, and co-expressed them with LRP16 in SW480 cells. A deletion
analysis demonstrated that the C-terminal catalytic domain of PKR mediated its physical interaction
with LRP16 (Figure 4D). To map the regions in LRP16 that interacted with PKR, we generated a
series of LRP16 deletion mutant constructs and co-expressed them with PKR in SW480 cells.
Figure 4E shows that the macrodomain of LRP16 retained is ability to interact with PKR.
Next, we performed a glutathione S-transferase (GST) pull-down assay using GST-fused LRP16
and in vitro-transcribed and -translated components of WT PKR and PKR deletions. Our pull-down
assays using the recombinant proteins demonstrated a direct LRP16–PKR interaction (Figure 4F).
Similarly, in vitro GST pull-down assays indicated that almost all PKR fragments, except DPKc,
directly bound to LRP16. In contrast to the strong association between LRP16 and full-length PKR,
the DPKc-truncated PKR protein interacted negligibly with LRP16 (Figure 4G), further supporting
the critical role of the C-terminus of PKR in the LRP16–PKR interaction. Intriguingly, according to our
LC–MS/MS data, IKKb with two matching peptides potentially interacted with LRP16 (Figure 4A).
Consistent with this finding, previous studies have shown that PKR binds specifically to the IKKb sub-
unit of the IKK complex and mediates the activation of NF-kB (Bonnet et al., 2000; Zamanian-
Daryoush et al., 2000). To investigate whether the physical associations between LRP16 and PKR or
IKKb reflected a capacity of LRP16 to interact with both the PKR and IKKb proteins simultaneously,
or whether LRP16 interacted with either PKR or IKKb in different cellular environments, a GST pull-
down assay was performed using GST-fused LRP16 and in vitro-transcribed and -translated compo-
nents of PKR and IKKb. The assay indicated that LRP16 was capable of interacting directly with both
PKR and IKKb, but independently with each (Figure 4H). Together, these experiments not only
showed the molecular details involved in the interaction between LRP16 and PKR, but also provided
additional support for the physical associations among LRP16, PKR, and IKKb in vitro.
We further identified the contribution of LRP16 to the assembly of this PKR–IKK kinase complex.
Notably, depletion of LRP16 introduced by its siRNAs resulted in the significant attenuation of the
PKR–IKKb interaction, both at baseline and after stimulation with etoposide (Figure 4I), suggesting
that LRP16 was required for the formation of a ternary complex with PKR and IKKb. The link between
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Figure 4. LRP16 physically interacts with PKR/IKKb in the cytoplasm. (A) Mass spectrometry (MS) analysis of LRP16-associated proteins. Total cell lysate
of SW620 cells was subjected to affinity purification with an anti-LRP16 antibody. The purified protein complex was resolved with SDS-PAGE and silver
stained. The bands were excised, purified, and analyzed with MS. (B–C) Interactions of endogenous LRP16 with PKR were determined with a co-
immunoprecipitated (co-IP) analysis in SW480 cells treated with the indicated periods of etoposide. (D) SW480 cells transfected with the indicated
FLAG-tagged PKR deletion mutants and treated with etoposide for 30 min were subjected to immunoprecipitation with an anti-FLAG antibody. The
lysates and immunoprecipitates were analyzed. (E) Cells transfected with the indicated constructs were subjected to immunoprecipitation with an anti-
FLAG antibody. The lysates and immunoprecipitates were then blotted. (F) Bacterially expressed glutathione S-transferase (GST)–LRP16 fusion protein
was purified on glutathione agarose beads; 10% of the beads were analyzed with SDS-PAGE and Coomassie Brilliant Blue staining. The remaining
beads containing the GST–LRP16 fusion protein were used to pull down in vitro-translated FLAG–PKR. The interactions were detected with SDS-PAGE
and immunoblotting. (G) In vitro-translated FLAG–PKR deletion mutants were incubated with GST or GST–LRP16–GSH–Sepharose. Proteins retained on
the Sepharose were blotted with the indicated antibodies. (H) In vitro-translated PKR and IKKb were incubated with GST or GST–LRP16–GSH–
Sepharose. Proteins retained on the Sepharose were blotted with the indicated antibodies. (I) SW620 cells transfected with the indicated siRNAs were
Figure 4 continued on next page
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PKR and TP53 has been described most frequently in cancer cells, in which there is a bidirectional
and complex regulatory relationship between the two proteins (Cuddihy et al., 1999). Unexpect-
edly, the interaction of endogenous LRP16 with the PKR protein was confirmed after etoposide
treatment in TP53-null cells (Figure 4—figure supplement 1A), suggesting that the interaction
between the two proteins did not depend on the presence of p53 under these conditions.
To understand how LRP16 drives NF-kB activity in association with the cytoplasmic proteins IKKb
and PKR, we used confocal microscopy to observe the intracellular distribution of LRP16 during eto-
poside, camptothecin, doxorubicin or IR stimulation. After stimulation, both endogenous and exoge-
nous LRP16 dispersed from the nucleus to the cytosol (Figure 4—figure supplement 1B–C). We
also prepared nuclear and cytoplasmic fractions from cells treated with etoposide or IR for various
times, and examined each for the presence of LRP16. These cells also revealed the dynamic disper-
sion of LRP16 from the nucleus to the cytosol (Figure 4—figure supplement 1B–C). More impor-
tantly, the translocation of LRP16 was also detected after genotoxic stress in other tumor cells,
including breast cancer and lung cancer cells (Figure 4—figure supplement 1D). The kinetics of
LRP16 translocation were consistent with the dynamic changes in both IKKa and KKb phosphoryla-
tion in response to etoposide stimulation, suggesting that LRP16 was possibly required for the
assembly and activation of the IKK complexes triggered by DNA damage. To test this possibility, we
prepared nuclear and cytoplasmic fractions from cells treated with etoposide for different times and
used co-IP to pull down both endogenous and exogenous LRP16 from the control cells and cells
expressing FLAG-tagged LRP16 in the presence or absence of etoposide. As shown in Figure 4J
and K, in the etoposide-treated cells, the interactions of both endogenous and exogenous LRP16
with PKR and IKKb were observed and confirmed by co-IP only in cytoplasmic fractions, but they
were negligible in the nuclear fractions. Notably, the overexpression of FLAG-tagged LRP16 in
SW480 cells upon exposure to etoposide increased the interaction between PKR and IKKb detected
with co-IP, but only in the cytoplasmic fractions, with negligible effects in the nuclear fractions
(Figure 4L). This finding suggests that LRP16 plays an important role in the recruitment of PKR and
IKKb into a physical complex that facilitates the downstream signaling of NF-kB.
We then asked whether the intracellular trafficking of LRP16 occurs in response to stimulation
with TNFa. In contrast to the etoposide-induced translocation of LRP16 to the cytoplasm, the trans-
location of LRP16 was completely abrogated by stimulation with TNFa (Figure 4—figure supple-
ment 1E). The IR and/or etoposide-induced shift of LRP16 into the cytoplasmic complex fractions
was completely blocked both by PARP inhibitors (3-AB or PJ-34) and by the PAR-binding-deficient
mutant LRP16_I161A (Figure 4—figure supplement 1F), suggesting that this process strictly
depends on the presence of PAR and the intact PAR-binding motifs in LRP16. Our data suggest that
upon the detection of DNA lesions and PAR, LRP16 assembles the PKR and IKKb complex in the
cytoplasm. This complex could be formed by direct protein–PAR interactions, as well as by protein–
protein interactions. The PAR chains bound to LRP16 act as an interaction platform, which is
required for PKR-mediated IKK activation and the activation of the NF-kB pathway in response to
DNA damage.
Figure 4 continued
treated with etoposide before collection. PKR was immunoprecipitated with an anti-PKR antibody and immunoblotted with the indicated antibodies. (J–
K) Cytosolic and nuclear fractions derived from SW620 cells (J), and cytosolic and nuclear fractions derived from SW480 cells expressing exogenous
FLAG–LRP16 (K), were treated with etoposide (50 mM) for the indicated periods, and immunoprecipitated and immunoblotted with the indicated
antibody. (L) Cytosolic and nuclear fractions derived from SW480 cells transfected with vector expressing FLAG–LRP16 or the control vector were
treated with etoposide (50 mM) for the indicated periods, and immunoprecipitated and immunoblotted with the indicated antibody. One representative
experiment of three was shown.
DOI: 10.7554/eLife.27301.015
The following figure supplement is available for figure 4:
Figure supplement 1. LRP16 physically interacts with PKR in a TP53 independent manner, and nucleocytoplasmic shuttling of LRP16 in response to
DNA damage, not TNFa signaling depends on PAR.
DOI: 10.7554/eLife.27301.016
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Crosstalk between LRP16 and PKR is critical for genotoxicity-induced
NF-kB activation
We were particularly interested in how LRP16 drives the activation of the IKK kinases by PKR. We
found that PKR is ubiquitously expressed in CRC cell lines (Figure 5—figure supplement 1A). How-
ever, the exact role of PKR in cancer biology remains controversial, and thus we ascertained the PKR
protein levels with IHC using a human tissue array containing 202 CRC samples with paired adjacent
normal colon tissues. Analysis of these data showed that the level of PKR expression was significantly
elevated in the carcinoma tissues relative to that in the adjacent tissues (Figure 5A). Moreover, PKR
was highly elevated in primary CRC tumors compared with their adjacent normal tissues as deter-
mined by RT-PCR and Western blot analysis and, noticeably, also positively correlated with the histo-
logical grades of the CRC patients (Figure 5—figure supplement 1A), which is consistent with the
previous study (Kim et al., 2002). Further analysis of consecutive tissue sections showed that LRP16
expression positively correlated with PKR expression. Specifically, approximately 75% of the samples
with high LRP16 expression also displayed high PKR expression, and approximately 58% of the low
LRP16 samples displayed low PKR expression (Figure 5B).
Chemotherapeutic drugs, especially etoposide, activated PKR in CRC cell lines (Figure 5—figure
supplement 1B–C), although the molecular mechanism that underlies PKR activation remains to be
clarified. We then asked whether LRP16 affects the PKR activity induced by etoposide. Cells ectopi-
cally expressing LRP16 profoundly enhanced the PKR activity induced by etoposide in a time- and
dose dependent manner (Figure 5C). Conversely, LRP16 depletion introduced by its siRNAs dramat-
ically blocked the etoposide-induced activation of PKR (Figure 5D). We then examined whether the
PAR-binding ability of LRP16 is also critical for PKR activation induced by DNA damage. Upon expo-
sure to etoposide, the introduction of LRP16 WT, but not its mutants LRP16_D160A or LRP16_I161A,
profoundly increased the activation of PKR, as evidenced by the level of its autophosphorylation,
without affecting its total protein level (Figure 5E), suggesting that the PAR-binding activity of
LRP16 is also required for the DNA-damage-induced PKR activity.
Next, we hypothesized that the interaction between LRP16 and IKKb and NF-kB activity is
required for or dependent on the activation of PKR. Western blot analysis showed that knockdown
of PKR introduced by its siRNAs reduced the phosphorylated forms, but not the total forms, of the
upstream regulators of the NF-kB pathway, IKKa and IKKb, which are induced by LRP16 upon expo-
sure to etoposide (Figure 5F), and also impaired the interaction between LRP16 and IKKb after eto-
poside treatment (Figure 5—figure supplement 1D), suggesting that PKR acts as an adaptor
protein and may be critical for the LRP16-mediated activation of IKK in response to DNA damage.
Similarly, upon IR stimulation, depletion of PKR significantly abrogated the activation of NF-kB medi-
ated by LRP16 (Figure 5G). To determine whether both LRP16- and PKR-dependent signaling to
NF-kB was channeled by IKK, we used siRNAs targeting either LRP16 or PKR to repress their expres-
sion, and performed a kinase array analysis in vitro. Noticeably, the etoposide-induced activation of
IKK kinases was significantly reduced in the absence of either LRP16 or PKR expression (Figure 5H),
suggesting that the formation and integration of the ternary complex containing LRP16, PKR, and
IKK kinases plays a crucial role in the DNA-damage-induced transactivation of NF-kB. To investigate
the physiological role and the influence of PKR on the cellular behavior of CRC cells, we analyzed
the effect of a loss-of-function PKR on cell survival and proliferation after etoposide treatment. The
results of cell viability and clonogenicity assays showed that the effect of LRP16 overexpression on
the resistance of CRC cells to etoposide was offset, at least in part, when PKR was simultaneously
depleted (Figure 5I and Figure 5—figure supplement 1E). Similarly, knocking down PKR in cells
expressing LRP16 re-sensitized the cells to etoposide-induced DNA damage, when measured by
Annexin-V/PI binding assay. Meanwhile, this phenomenon was accompanied by elevated level of
caspase three cleavage (Figure 5J and Figure 5—figure supplement 1F).
Whether NF-kB activation requires the catalytic activity of PKR is still contentious (Bonnet et al.,
2000; Ishii et al., 2001; Zamanian-Daryoush et al., 2000). Thus, we next ascertained whether the
catalytic activity of PKR is required for the LRP16-mediated activation of IKK complexes during geno-
toxic stress. Notably, the inhibition of PKR catalytic activity with the chemical inhibitor 2-aminopurine
(2-AP) had no significant effect on the activation of IKK induced by LRP16 after DNA damage (e.g.
etoposide or IR) (Figure 5—figure supplement 1G–H), but it markedly inhibited the phosphoryla-
tion of IkBa (Figure 5—figure supplement 1G), which is consistent with a previous study that
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Figure 5. LRP16 PAR-dependently activates PKR and confers NF-kB activation induced by DNA damage. (A) Representative images of the IHC staining
of PKR expression in CRC tissues and matched adajcent tissues from a tissue array containing 202 CRC samples paired with adjacent normal colon
Figure 5 continued on next page
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suggested that PKR directly phosphorylates IkBs (Kumar et al., 1994). These data together demon-
strate that PKR activates IKK via a direct protein–protein interaction, possibly via the IKKb subunit,
rather than by its kinase activity. Thus, LRP16 activates the NF-kB signaling pathway via its interac-
tion with and activation of PKR, which acts as an adaptor protein and activates IKK complexes in
response to DNA-damaging cytotoxic therapies.
Screening of small molecules targeting the macrodomain of LRP16
Our aforementioned results favor a model in which LRP16-mediated PKR/NF-kB activation via pro-
tein interactions limits the response of CRC cells to etoposide. We were particularly interested in the
implications of this for the development of strategies to optimize the therapeutic benefits of DNA
damage in CRC. Therefore, we identified small molecules that can inhibit the LRP16-mediated acti-
vation of the PKR/NF-kB pathway and small molecule inhibitors that suppress the proliferation of
CRC both ex vivo and in vivo.
Several chemical libraries containing hundreds of compounds with different structures were
screened, and their ability to dock with the structural pocket of the macro domain region of LRP16
(amino acids [aa] 153–319; PDB ID code: 2  47) was examined using the University of California,
San Francisco (UCSF) DOCK 6.1 program suite (Figure 6—figure supplement 1A). The small mole-
cules were ranked according to their energy scores. Among these small molecules, two compounds,
MRS2578 (C20H20N5S4, molecular weight [MW] 472.67), a potent P2Y6 receptor antagonist
(Syhr et al., 2014), and NECA (C12H16N6O4, MW 308.29), a potent adenosine receptor agonist
(Ye et al., 2016), were identified as competitive inhibitors of the affinity of LRP16 for PAR (Fig-
ure 6—figure supplement 1B). In this context, we have previously shown that the PAR-binding abil-
ity of LRP16 plays an essential role as a spatial regulator of PKR/NF-kB signals by orchestrating the
extranuclear signaling of IKK. Accordingly, we found that IKKb kinase activity was markedly attenu-
ated in IR-stimulated cells pretreated with these two compounds or the PARP inhibitors 3-AB and
PJ-34 (used as positive controls) compared with that in IR-stimulated control cells. However, the inhi-
bition of IKKb kinase activity by NECA was less efficient than MRS2578 (Figure 6—figure
Figure 5 continued
tissues. The outlined areas in the left images are magnified on the right. Scale bars, 50 mm. PKR expression scores are shown as scatter dot plots. We
compared the CRC tissues with the matched adjacent normal colon tissues using a Wilcoxon matched pairs test. N = 202. Error bars represented the
mean ± SD. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. (B) Representative images of IHC staining for LRP16 and PKR in two serial sections from the
same tissue samples. Scale bars, 50 mm. Positive correlation between LRP16 and PKR protein levels. The 202 samples were classified into two groups
(low LRP16, N = 87; high LRP16, N = 115) based on the LRP16 level relative to the score for the whole cohort. p<0.001, calculated by both c2 and
Mann–Whitney tests. Pearson’s correlation between LRP16 and PKR expression levels (N = 202; p<0.0001; R2 = 0.09373). (C) Whole cell lysates from
SW480 cells transfected with an LRP16-expressing plasmid or control vector were treated with the indicated concentrations of etoposide for 2 hr or with
50 mM etoposide for the indicated periods, and immunoblotted with the indicated antibody. b-Actin was used as the loading control. (D) Lysates from
cells transfected with LRP16 siRNAs or control siRNAs and treated with the indicated concentrations of etoposide for 2 hr or with 50 mM etoposide for
the indicated periods were immunoblotted with the indicated antibody. b-Actin was used as the loading control. (E) Cells were transfected with control
vector or vector expressing LRP16 or the LRP16 mutants (LRP16_D160A or LRP16_I161A) and treated with the indicated concentrations of etoposide for
2 hr (left) or etoposide (50 mM) for the indicated periods (right). The cell lysates were immunoblotted with the indicated antibody. (F) SW480 cells either
overexpressing LRP16 or transfected with the control vector were cotransfected with the indicated PKR siRNAs and treated with etoposide for 2 hr.
Their lysates were immunoblotted with the indicated antibody. b-Actin was used as the loading control. (G) Cells were co-transfected with the indicated
plasmids and/or siRNAs and were treated with IR at the indicated doses, with or without subsequent BAY 11–7082 treatment. Their lysates were
immunoblotted with the indicated antibody. (H) In vitro kinase assay. SW620 cells were mocked transfected or transfected with the indicated siRNAs,
treated with etoposide for the indicated periods, and then analyzed with an IKK kinase assay using GST–IkBa as the substrate. (I) Cells were
cotransfected with the indicated plasmids and/or siRNAs, treated with etoposide, and subjected to cell viability analysis and clonogenic cell survival
assays. (J) Cells were co-transfected with the indicated plasmids and/or siRNAs and treated with etoposide at the indicated concentrations. Their
lysates were separated with SDS-PAGE and analyzed with Western blotting using the indicated antibody. b-Actin was used as the loading control. One
representative experiment of three was shown.
DOI: 10.7554/eLife.27301.017
The following figure supplement is available for figure 5:
Figure supplement 1. PKR is elevated in CRC samples and is activated in response to DNA damage, and intact PKR, but not its kinase activity is
required for the DNA damage-induced NF-kB activity.
DOI: 10.7554/eLife.27301.018
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supplement 1B). Therefore, the small molecule MRS2578 conformed to our requirements and lim-
ited the activation of NF-kB induced by DNA damage.
MRS2578 induces cell killing and abrogates LRP16-mediated NF-kB
activation in response to etoposide
To investigate the antitumor effect of MRS2578 in CRC cells ex vivo, CCK-8 assays were conducted
to assess the growth of six CRC cell lines (RKO, LS180, HCT116, SW1116, SW480, and LoVo) after
treatment with MRS2578. As indicated in Figure 6A, MRS2578 treatment for 24 hr markedly and
dose-dependently reduced the viability of the CRC cell lines. Consistent with this finding, a signifi-
cantly lower percentage of 5-ethynyl-2’-deoxyuridine (EdU)-incorporated (proliferating) cells was
observed in the MRS2578-treated cells than in the control cells (Figure 6B). MRS2578 also markedly
suppressed the proliferation in the CRC cells, as evidenced by their reduced clonogenic survival
(Figure 6C and Figure 6—figure supplement 1C). Collectively, these data show that MRS2578
inhibits the survival and proliferation of CRC cells in vitro.
We next wondered whether MRS2578 could kill CRC cells by inactivating the LRP16-mediated
activation of NF-kB induced by etoposide, and thus sensitizing the tumor cells to DNA-damaging
cytotoxic therapies. Of note, etoposide-induced the activation of NF-kB, as judged by the phosphor-
ylation forms of IKKa and IKKb, p65, and IkBa, but not the total form, was significantly and dose-
dependently inhibited when cells were pretreated with MRS2578 (Figure 6D and Figure 6—figure
supplement 1D). Taken together, these results suggested that CRC pretreated with MRS2578 indu-
ces cell killing and abrogates LRP16-mediated NF-kB activation in response to etoposide, leading to
conversion of LRP16 from a survival into a killer molecule.
Combination drug administration induces synergistic cytotoxicity ex
vivo
To evaluate whether MRS2578 increased the sensitivity of CRC cells to etoposide, we first assessed
the responses of CRC cells to a combination of etoposide and MRS2578 or each drug alone. At an
unfixed ratio, the concentrations of MRS2578 and etoposide spanning the IC50 of each cell line were
selected for a combination study in which we calculated the combination index (CI) values with the
ComboSyn software (CI <1, synergistic; CI = 1, additive; and CI >1, antagonism) (Chou, 2010). To
more accurately analyze the degree of synergy between etoposide and MRS2578, a CI value was cal-
culated. Of note, both SW480 and HCT116 cells treated with the combination of the two drugs
showed synergistic cytotoxicity when assessed with the CalcuSyn model (Figure 6E). Cells stably
overexpressing LRP16 displayed less sensitivity to etoposide alone than control cells, but these cells
were even more sensitive to a combination of etoposide and MRS2578 (Figure 6F–G). To further
assess whether the synergistic inhibition of cell proliferation by MRS 2578 and etoposide was modu-
lated by enhanced apoptosis, we performed an Annexin-V/PI binding assay. Notably, the protection
against apoptosis afforded by LRP16 overexpression in response to etoposide was offset, at least
partially, when MRS2578 was used stimultaneously (Figure 6H). Additionally, results from cell-cycle
profiling revealed that both cells stably expressing LRP16 and the control pretreated with MRS2578
displayed significant reductions in the proportions of cells in G0/G1 phase and showed significantly
increased in the percentages of the cells in G2 phase (Figure 6I). These findings reveal that
MRS2578 increases the sensitivity of CRC cells to etoposide by enhancing their apoptosis and inhib-
iting cell growth.
To further investigate whether MRS2578 increased the sensitivity of CRC cells to IR, we selected
two cell lines (DLD1 and HT-29) and exposed them to IR over time until resistance emerged, to gen-
erate the two cell lines DLD1_R (parental DLD1) and HT-29_R (parental HT-29). Compared with their
parental cells, both the DLD1_R and HT-29_R cells were substantially sensitized to MRS2578
(Figure 6J), indicating that the cytostatic effect of MRS2578 (by inducing apoptosis and reducing
cell growth) contributed to increasing the sensitivity or reducing the resistance of the cells to IR, and
that the cytostatic effect was also independent of the IR resistance mechanism.
Our next step was to understand how MRS2578 blunts genotoxicity-induced NF-kB activation in
CRC and significantly sensitizes tumor cells to DNA-damaging cytotoxic therapies. We have shown
that LRP16, interacting with PKR, plays a role in extranuclear NF-kB signaling, but not in nuclear NF-
kB signaling, during the DNA damage response. Using LRP16 mutants (D160A and I161A), which
Li et al. eLife 2017;6:e27301. DOI: 10.7554/eLife.27301 17 of 34
Research article Cancer Biology Cell Biology
Figure 6. MRS2578 impairs LRP16-mediated NF-kB activity induced by DNA damage, inhibits cells proliferation, and enhances the cytotoxic effects of
etoposide. (A) MRS2578 inhibits CRC cell viability. Cell viability was measured with the CCK-8 assay in RKO, LS180, HCT116, SW1116, SW480, and LoVo
Figure 6 continued on next page
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function in a dominant inhibitory fashion by impeding the PAR-binding ability of LRP16, significantly
reduced etoposide-induced NF-kB activity (Figure 3F). Thus, we evaluated the effect of MRS2578
on genotoxicity-induced NF-kB signaling and it is possible that this inhibitor behaves in similar fash-
ion by impeding the PAR-binding ability of LRP16 to impede NF-kB activity. Of note, cells pre-
treated with MRS2578 significantly impeded the phosphorylation of IKKa and IKKb induced by
etoposide, similar to the phenomenon detected in cells stably expressing D160A and I161A
(Figure 6D). Pretreating cells with MRS2578 profoundly reduced both the etoposide-stimulated
phosphorylation of IKKa and IKKb and the etoposide-stimulated autophosphorylation of PKR
(Figure 6K). Furthermore, it also inhibited the etoposide-stimulated interaction among LRP16, PKR,
and IKKb and thus prevented the formation of a ternary complex, which might eventually impede
the PKR activation of IKK (Figure 6—figure supplement 1E). Taken together, these results sug-
gested that inhibiting the binding of LRP16 to PAR or pretreating cells with MRS 2578 is as effective
as inhibiting PKR activity in blocking the biochemical effects of PKR in the cytoplasm and in inhibiting
the NF-kB activity induced by LRP16 in response to DNA damage.
Blockade of LRP16/NF-kB signaling inhibits the tumorigenicity of CRC
cells in vivo
In light of our ex vivo findings, we examined the effect of LRP16 knockdown in vivo. Stable knock-
down of LRP16 introduced by its shRNAs in SW620 cells suppressed tumor growth in the subcutane-
ous xenograft model. The mean weight of LRP16-silenced tumors was also reduced in SW620 cells
compared with controls (Figure 7A and Figure 7—figure supplement 1A–B). Of note, compared
with controls, stable knockdown of LRP16 was not only associated with a significant reduction in the
growth of the primary SW620 tumors, but also with a marked increase in the sensitivity of the xeno-
graft tumors to etoposide treatment (Figure 7A and Figure 7—figure supplement 1B). Silencing of
LRP16 at mRNA levels in SW620 were verified by qPCR (Figure 7—figure supplement 1C). Body
weight measurements made during the study indicated that etoposide treatment was tolerated by
the animals (Figure 7—figure supplement 1D). Knockdown of LRP16 significantly inhibited cell pro-
liferation and sensitized tumor cells to etoposide in SW620 cell xenograft models, as determined by
Ki-67 staining. SW620 xenografts stably expressing shLRP16 showed the induction of apoptosis fol-
lowing etoposide treatment, as evidenced by the increased expression of terminal deoxynucleotidyl
transferase dUTP nick-end labeling (TUNEL) (Figure 7B). Similar results were also obtained after IR
treatment of the mouse xenograft tumors (Figure 7—figure supplement 2A–E), indicating that the
expression of LRP16 is not only required, but also sufficient to promote radio-resistance in a CRC
Figure 6 continued
cell lines treated with the indicated concentrations of MRS2578 for 72 hr. (B) MRS2578 inhibited the proliferation of CRC cell lines, measured with EdU
labeling, when the cells were treated with the indicated concentrations of MRS2578. (C) Colony formation assays: MRS 2578 suppressed colony
formation in several CRC cell lines. Cells were cultured with the indicated concentrations of MRS2578 for 10 days. (D) SW480 cells transfected with the
LRP16-overexpressing vector or control vector were pretreated with increasing amounts of MRS2578 for 90 min, and then with etoposide for 2 hr. Their
lysates were immunoblotted with the indicated antibody. b-Actin was used as the loading control. (E) SW480 cells and HCT116 cells were treated with
dual etoposide (5–20 mM) and MRS2578 (2.5–10 mM). The cells were treated daily for 3 days with the indicated drug combinations, and then assayed
with CCK-8 to determine the cytotoxicity of the treatments. X axis, fraction of cells affected (Fa); y axis, combination index (CI). Combinations with CI <1
are synergistic. (F–H) Cells transfected with the control vector or a plasmid expressing LRP16 were treated with etoposide alone or in the presence of
MRS2578, and subjected to cell viability analysis (F), a clonogenic cell survival assay (G), and cell apoptosis analysis (H), Error bars in (H) represented the
mean ± SD for triplicate experiments. *p<0.05, **p<0.01, ns, not significant. (I) Cell-cycle analysis: Flow-Cytometric analysis of the cell-cycle profiles of
SW480 cells overexpressing LRP16 or transfected with the control vector in the presence of MRS2578. (J) Cell viability assay: two CRC cell lines (DLD1
and HT-29) were exposed over time to IR until resistance emerged, generating the two cell lines DLD1_R (parental DLD1) and HT-29_R (parental HT-29).
Cell viability was measured with the CCK-8 assay in the presence of MRS2578. (K) SW480 cells transfected with the control vector or with LRP16-
expressing vector or the LRP16 mutants (LRP16_D160A or LRP16_I161A) were treated with etoposide alone or in the presence of MRS2578. Their lysates
were immunoblotted with the indicated antibody. One representative experiment of three was shown.
DOI: 10.7554/eLife.27301.019
The following figure supplement is available for figure 6:
Figure supplement 1. A small molecule MRS2578 inhibits the NF-kB activity induced by LRP16, and disrupts the interactions of the LRP16, PKR, and
IKKb complex in response to DNA damage.
DOI: 10.7554/eLife.27301.020
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Figure 7. LRP16 deficiency sensitizes CRC to DNA-damaging cytotoxic therapies and combination of MRS2578 and etoposide synergistically represses
CRC in xenograft models. (A) nu/nu nude mice were transplanted with 1  106 SW620 cells infected with a lentivirus carrying either control shRNA or
LRP16 shRNA. When the tumors were established, mice with tumor sizes > 150 mm3 (n = 5 per group) were treated with the control or etoposide (20
mg/kg intraperitoneal injection) for the indicated numbers of days. The sizes of the tumors were measured every 3 days with a Vernier caliper. (B)
Representative immunohistochemical (IHC) staining for TUNEL and Ki67 in tumor tissues under the indicated conditions. The bar denotes 50 mm. Error
bars in (A) and (B) represented the mean ± SD for triplicate experiments. *p<0.05, **p<0.01, ***p<0.001. (Ca–Cc) nu/nu nude mice with CRC cell
xenografts were treated with increasing doses of MRS2578 (0, 10, or 20 mg/kg) twice a week for 28 days. Tumor volumes and bodyweights were
measured weekly. At the end of the study, the mice were killed, and the tumors were removed and analyzed. All p values were compared with the
control group. Error bars indicated the mean ± SD for triplicate experiments. *p<0.05, **p<0.01, ***p<0.001. (D) nu/nu nude mice were transplanted
with CRC cells infected with a lentivirus carrying either control shRNA or LRP16 shRNA. When the tumors were established, the mice with tumor
sizes > 150 mm3 (n = 6 per group) were treated with the control or etoposide (20 mg/kg intraperitoneal injection) and/or MRS2578 (10 mg/kg
intraperitoneal injection) for the indicated number of days. Tumor volumes (Da), representative bright-field images of the tumors (Db), Representative
IHC staining for Ki-67 in tumor tissues from mice after treatment with MRS2578 or a combination of etoposide and MRS2578. Scale bar represents 50
mm (Dc), representative tumors were isolated at the end of the assay, and tissue lysates were immunoblotted with the indicated antibodies (Dd). (E)
BALB/c mice were implanted with CT26 colorectal adenocarcinoma cells. When the tumors were established, the mice with tumor sizes > 150 mm3
(n = 6 per group) were treated with the control, MRS2578, etoposide, or a combination of etoposide and MRS2578, for the indicated number of days.
Error bars in (D) and (E) represented the mean ± SD for triplicate experiments.*p<0.05, **p<0.01, ***p<0.001. (F) Kaplan–Meier survival curves for BALB/
c mice implanted CT26 colorectal adenocarcinoma xenografts after treatment with the control, MRS2578, etoposide, or a combination of etoposide
and MRS2578. *p<0.05, **p<0.01, ***p<0.001. One representative experiment of three was shown.
DOI: 10.7554/eLife.27301.021
The following figure supplements are available for figure 7:
Figure 7 continued on next page
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tumor model. Collectively, knockdown of LRP16 is synthetically lethal in CRC in vivo through sup-
pressing cell growth and sensitizing the tumor to genotoxicity therapies.
MRS2578 suppresses CRC growth in mouse xenograft models
Based on our findings obtained in cell culture models ex vivo, we next evaluated the anti-tumor
effects of MRS2578 in mouse xenograft models in vivo. We first analyzed the toxicity of MRS2578 in
mice. To define the appropriate doses for the in vivo experiments, mice were administered intraperi-
toneal injections of MRS2578 at tolerable doses (10 mg/kg or 20 mg/kg), as previously described
(Syhr et al., 2014). At these doses, NF-kB activity could be inhibited in our cell culture models
(Figure 6D and Figure 6—figure supplement 1D). The dose range between 10 and 20 mg/kg was
tolerable, with no deaths recorded for up to 12 days of twice weekly administration. To test the
potency of MRS2578 in vivo, CRC xenografts derived from SW620 cells were treated with increasing
doses (0, 10, and 20 mg/kg, twice weekly) of MRS2578 via the intraperitoneal route for 28 days. The
results showed that treatment of mice with MRS2578 resulted in a dose-dependent repression of
CRC in vivo (Figure 7Ca–Cb). Hematoxylin and eosin (H and E) staining of the tumor tissues showed
that the number of cells was substantially reduced in the tumors treated with MRS2578, and that the
tumors were filled with fibrosis-like tissue. Consistent with this finding, an IHC analysis indicated that
the expression of Ki67 was profoundly reduced in the tumor cells treated with MRS2578
(Figure 7Cc). No significant weight loss or organ toxicities were observed in the mice treated with
MRS2578 (Figure 7—figure supplement 3Aa–Ab). These findings suggest that doses between 10
and 20 mg/kg provide the optimal therapeutic index for MRS2578 for in vivo experimentation involv-
ing CRC xenografts.
MRS2578 synergizes with etoposide in the suppression of CRC in vivo
As further evidence for the important translational implications of the present studies, in in vivo ther-
apy models in immune-deficient mice, our combinations of etoposide and MRS2578 yielded potent
antitumor responses. First, for SW620 cells xenografts, as expected, mice treated with etoposide
alone showed a significant reduction in tumor burden versus those treated with vehicle alone. How-
ever, the combination (simultaneous drug administration) treatment yielded a further tumor burden
reduction compared with vehicle or etoposide alone (Figure 7Da–Db and Figure 7—figure supple-
ment 3Ba–Bb). The treatment was well tolerated, as no significant weight loss and no organ toxic-
ities were observed in mice that received these treatments, including combined treatment,
throughout the study (Figure 7—figure supplement 3Ba–Bb). Of note, the combination of etopo-
side and MRS2578 resulted in significantly greater growth inhibition, as determined by Ki-67 staining
(Figure 7Dc). Lastly, we also checked the effects of the small molecule inhibitor MRS2578 on onco-
genic NF-kB signaling in xenograft tumors. As expected, phospho-p65 levels, but not total forms,
are clearly decreased in the compound MRS2578 treated groups (Figure 7Dd). These results are
consistent with the observations in the CRC cell experiments ex vivo.
We also investigated the combined effects of etoposide and MRS2578 on CT26 colorectal adeno-
carcinomas (BALB/c origin) implanted into BALB/c mice. Both the therapeutic effect and safety pro-
file were evaluated. As expected, treatment with the combination of etoposide and MRS2578
further reduced tumor growth, indicating that this combination was more active than either single
agent alone in inhibiting CRC cell growth and significantly prolonged mouse survival (Figure 7E–F
and Figure 7—figure supplement 3C). There were no significant reductions in the mouse
Figure 7 continued
Figure supplement 1. LRP16 deletion sensitizes CRC to etoposdie in xenograft models.
DOI: 10.7554/eLife.27301.022
Figure supplement 2. LRP16 deficiency sensitizes CRC to IR in vivo.
DOI: 10.7554/eLife.27301.023
Figure supplement 3. Evaluation of the toxicity and antitumor efficacy of MRS2578 in vivo and combination of MRS2578 and etoposide has no
significant toxicity in vivo.
DOI: 10.7554/eLife.27301.024
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bodyweights, indicating that the toxicity of this combination is controllable (Figure 7—figure sup-
plement 3C).
Taken together, these findings show that pharmacologically targeting LRP16/NF-kB signaling pre-
vents tumorigenesis and suggest that the combination of MRS2578 and etoposide offers therapeutic
opportunities for CRC and may warrant an immediate clinical trial.
Discussion
As our understanding of the molecular basis of cancer has improved, a number of dysregulated sig-
naling pathways responsible for driving disease progression have been identified. Efforts have been
made to exploit these pathways as targets for therapeutic intervention, with the expectation that
drugs capable of modulating them would deliver previously unachievable efficacy. However, the
genetic instability and hypermutation rates of cancer, coupled with the redundancy often built into
biological systems, have undermined the importance of singular targets. In the presence of this con-
fluence of factors, resistant mutations arise and compensatory signaling pathways become upregu-
lated, limiting the utility of specific inhibitors (Ribic et al., 2003). These observations suggest that
while the development of new targets is critical, priority should be given to those that have the
potential to act in synergy with and increase the therapeutic index of established treatment modali-
ties. LRP16, as a cofactor for multiple nuclear receptors, fits this description (Han et al., 2011).
LRP16 initially attracted attention because of the foundamental roles it plays in driving tumor pro-
gression; however more recently, relationships between the cofactor and other disease pathways
have emerged. The intersection of these two features has thus made LRP16 an ideal oncology
target.
A key pathway linking DNA damage with apoptosis, senescence and DNA repair mechanisms
involves activating the NF-kB complex (Bernard et al., 2004; Hayden and Ghosh, 2008;
McCool and Miyamoto, 2012; Wan and Lenardo, 2010). It is widely accepted that genotoxicity-
induced NF-kB activation is initiated by both ATM and PARP1, which trigger the phosphorylation
and PIASy-mediated SUMOylation of nuclear NEMO. Our previous and present studies favor two
Figure 8. Schematic model of LRP16 function as a signaling molecule in the genotoxicity-initiated NF-kB signaling pathway. A model summarizing the
role of the LRP16/PKR/NF-kB core signaling axis in reducing the sensitivity of colon cancer cells to DNA-damaging therapies, and the synergistic effects
of MRS2578 and etoposide in suppressing CRC.
DOI: 10.7554/eLife.27301.025
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possible roles of LRP16 in activating NF-kB (Figure 8): first, LRP16 functions not only by providing
the lesion specificity during the cellular response to DNA damage by its unique interactions with
Ku70/Ku80, but also ensures the successful PARP1/PAR-dependent recruitment of both ATM and
PIASy, together with NEMO. These results underscore the function of LRP16, a versatile protein that
preferentially occurs in the nucleus, in the early nuclear signaling cascade following DNA damage;
second, when LRP16 detects DNA lesions and PAR, it assembles the PKR and IKKb complex, the key
players in NF-kB activation, in the cytoplasm. This complex can be formed by a direct protein–PAR
interaction, as well as by protein–protein interactions. The PAR chains bound to LRP16 act as an
interaction platform, which is required for PKR-mediated IKK activation and then activation of the
NF-kB pathway. Thus, LRP16 appears to have a dual function, which might at least partially explain
how these DNA-damage-initiated nuclear events are linked to the activation of cytoplasmic IKK.
Optimizing radiotherapy and chemotherapy for the treatment of malignant neoplasms has relied
on the iterative development and testing of models involving tumor growth dynamics, mutation
rates and cell-killing kinetics. However, the most theoretically effective tumoricidal strategies must
usually be tempered because of detrimental effects to the host. This reality has led to the develop-
ment of regimens in which therapies are administered at intervals or cycles to avoid irreparable dam-
age to vital host functions. However, the recovery and repopulation of tumor cells between
treatment cycles is a major cause of treatment failure (Kim and Tannock, 2005). Interestingly, rates
of tumor cell repopulation have been shown to accelerate in the intervals between successive
courses of treatment and solid tumors commonly show initial responses followed by rapid regrowth
and subsequent resistance to further chemotherapy. Understanding the resistance mechanisms
involved may open new therapeutic opportunities. Extensive previous research has demonstrated
that cancer cells develop resistance to platinum drugs in a variety of ways, including the following:
first, pre-target resistance, for instance, through the reduced accumulation or increased extrusion of
etoposide by transporters; second, on-target resistance, caused by DNA repair; third, post-target
resistance, through the modulation of DNA damage recognition, the damage response, and apopto-
sis; and fourth, off-target resistance, for example, through compensatory pro-survival signals or non-
specific adaptive responses that are not directly activated by drugs (Martin et al., 2008). The
apoptotic capacities of chemotherapeutic agents have been widely used to determine the responses
of cancer cells to them (Johnstone et al., 2002). Cellular apoptosis is a tightly regulated process
that is controlled by numerous signal transduction pathways, including the NF-kB pathway
(Johnstone et al., 2002). The NF-kB signaling pathway remains a very attractive target for pharma-
cological intervention because it has crucial functions in human health and disease, particularly in
inflammatory diseases and cancers (Hayden and Ghosh, 2008; Perkins, 2007; Smale, 2011). Collec-
tively, these studies support several conclusions: first, the outcomes of genotoxic exposures to any
specific benign or neoplastic cell depend on the integration of innate damage response capabilities
and the context that is dictated by the composition of the tumor microenvironment; second,
although intrinsic drug resistance is clearly operative in some cancers, acquired resistance can also
occur without alterations in intrinsic cellular chemosensitivity (Davis and Tannock, 2000; Kim and
Tannock, 2005); and third, specific tumor microenvironment that promote therapy resistance are
attractive targets for augmenting responses to more general genotoxic therapeutics. However, the
complexity of the damage response program also supports strategies that are focused on inhibiting
upstream master regulators, such as NF-kB, which may be more efficient and effective adjuncts to
cytotoxic therapies, provided their side effects are tolerable.
Clinically, PARP1 inhibitors are a very exciting spectrum of drugs that are currently used in cancer
management. Blocking the catalytic activity of PARP1 has been shown to inhibit base-excision repair
(BER), resulting in the accumulation of SSBs, as well as DSBs, during DNA replication, and this dam-
age, in turn, activates homologous recombination (HR) (O’Connor, 2015). Recent studies have
shown that the disruption of any HR-related pathway, such as by BRCA mutations, and disruption of
Fanconi anemia, and ATM genes, can predict the sensitivity of tumors to the inhibition of PARP1 by
small-molecule inhibitors and the associated cytotoxicity (D’Andrea, 2010; Mateo et al., 2015;
O’Connor, 2015; Pommier et al., 2016). Advances in understanding how and where, at a molecular
level, these agents function optimally as cytotoxic agents and the recent progress in developing the
best reagents are particularly important for the future use of PARP1 inhibitors in cancer therapy. The
clinically available PARP1 inhibitors have shown considerable efficacy, especially in the treatment of
breast and ovarian cancers, in patients with hereditary deletions of the HR BRCA1/2 genes
Li et al. eLife 2017;6:e27301. DOI: 10.7554/eLife.27301 23 of 34
Research article Cancer Biology Cell Biology
(Bryant et al., 2005; Farmer et al., 2005). Cancers presenting with these mutations represent 5–
10% of all triple-negative breast cancers (estrogen, progesterone, and HER2 receptor-negative
breast cancers; TNBCs) (Bryant et al., 2005; Farmer et al., 2005). However, the responses to PARP
inhibitor therapy, even in BRCA-mutant breast cancers, have not been highly persistent. Further-
more, PARP inhibitors have failed to show impressive clinical benefits in patients with sporadic
TNBCs and/or other cancers, suggesting that new strategies must be developed to maximize the
efficacy of PARP inhibitors (Lord and Ashworth, 2013).
In summary, we discovered a model in which LRP16 selectively interacts and activates PKR and
also acts as a scaffold to assist the formation of a ternary complex of PKR and IKKb, prolonging the
PAR-dependent NF-kB activation caused by genotoxic threats. Our preclinical data in CRC cell lines
and mouse xenografts, as outlined in this study, suggest the potential for improving the clinical effi-
cacies of DNA-damaging cytotoxic therapies by combining MRS2578 for patients with CRC. Our
studies convincingly demonstrate that using small molecules to interfere with the binding of LRP16
to PKR and IKKb, leading to the inactivation of its downstream NF-kB signaling pathways, is feasible
with regard to the suppression of the proliferation of human CRC cancer cells. Thus, our results
imply that LRP16 would not classically be viewed as ‘undruggable’, and open up an avenue that a
small molecule targeting LRP16 would be a promising strategy to combat CRC in future therapies.
Materials and methods
Ethics sataement
Human Subjects: The human patient study was approved by the Ethics Committee of the Chinese
PLA General Hospital (Beijing, China), and informed consent was obtained from all patients (S2016-
127-01). All samples were obtained in accordance with the Health Insurance Portability and Account-
ability Act (HIPAA).
Animal experimentation: This study was performed in strict accordance with the recommenda-
tions in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health,
and the protocol was approved by the Institutional Animal Care and Treatment Committee of the
Chinese PLA General Hospital (IACTC-CPGH-062). All surgery were performed under sodium pento-
barbital anesthesia, and every effort was made to minimize suffering.
Clinical tissue specimens and immunohistochemistry (IHC) analysis
The samples of carcinomas and adjacent normal tissues were obtained from surgical specimens from
patients with CRC for whom information on their clinicopathological characteristics were available
and were approved by the department of pathology at the Chinese PLA General Hospital and the
department of pathology at the Xiyuan Hospital of China Academy of Chinese Medical Sciences.
The samples were frozen in liquid nitrogen immediately after their surgical removal until analysis.
Colon tissue arrays were prepared and subjected to IHC analysis with the standard 3,30-diaminoben-
zidine (DAB) staining protocol. All experiments were approved by the Ethics Committee of the Chi-
nese PLA General Hospital (Beijing, China), and informed consent was obtained from all patients.
Cell lines, antibodies, and reagents
All human CRC cell lines HCT116 (ATCC Cat# CCL-247, RRID:CVCL_0291), DLD1 (ATCC Cat# CCL-
221, RRID:CVCL_0248), LoVo (ATCC Cat# CCL-229, RRID:CVCL_0399), LS180 (ATCC Cat# CL-187,
RRID:CVCL_0397), RKO (ATCC Cat# CRL-2577, RRID:CVCL_0504), SW48 (ATCC Cat# CCL-231,
RRID:CVCL_1724), CACO2 (ATCC Cat# HTB-37, RRID:CVCL_0025), HT-29 (ATCC Cat# HTB-38,
RRID:CVCL_0320), SW1116 (ATCC Cat# CCL-233, RRID:CVCL_0544), SW480 (ATCC Cat# CCL-228,
RRID:CVCL_0546), and SW620 (ATCC Cat# CCL-227, RRID:CVCL_0547) were obtained from the
American Type Culture Collection (ATCC) (Manassas, VA) and the identities have been authenticated
by short tandem repeat DNA profiling. All cells described above were regularly tested for myco-
plasma contamination. Cells were cultured in RPMI 1640 medium containing 10% fetal calf serum, 2
M glutamine, 100 U/ml each of penicillin and streptomycin. The following antibodies were used in
this study for immunoblotting and immunoprecipitation: antibodies directed against p-TAK1
(Thr184/187, Cat# 4508S, RRID:AB_561317) (1:1000), TAK1 (Cat# 5206S, RRID:AB_10694079)
(1:1000), p-IKKa/IKKb (Ser176/Ser177, Cat# 2078S, RRID:AB_2079379) (1:1000), IKKb (Cat# 2370S,
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RRID:AB_2122154) (1:1000), NEMO (Cat# 2695S, RRID:AB_10695250) (1:1000), p-p65 (Ser536, Cat#
3033S, RRID:AB_331284) (1:1000), p53 (7F5, Cat# 2527S, RRID:AB_10695803) (1:1000), p-IkBa
(Ser32/Ser36, Cat# 9246S, RRID:AB_2151442) (1:1000), PARP1 (46D11, Cat# 9532S, RRID:AB_
10695538) (1:1000), Caspase 3 (8G10, Cat# 9665S, RRID:AB_2069872) (1:1000), PKR (D7F7, Cat#
12297, AB_2665515) (1:1000), and NF-kB1 p105/p50 (D4P4D, Cat# 13586, AB_2665516) (1:1000)
were obtained from Cell Signaling Technology (Beverly, MA, USA); antibodies directed against p65
(Cat# sc-372, RRID:AB_632037) (1:1000), p50 (Cat# sc-114, RRID:AB_632034) (1:1000), p-JNK (Cat#
sc-81502, RRID:AB_1127391) (1:1000), JNK (Cat# sc-7345, RRID:AB_675864) (1:1000), GST (Cat# sc-
80998, RRID:AB_1124757), Sp1 (Cat# sc-17824, RRID:AB_628272) (1:2500), b-tubulin (Cat# sc-
53140, RRID:AB_793543) (1:2000), b-actin (Cat# sc-69879, RRID:AB_1119529) (1:2000), and glyceral-
dehde-3-phosphate dehydrogenase GAPDH (Cat# sc-166545, RRID:AB_2107299) (1:3000) were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA); antibody directed against p-PKR
(Thr446) (Cat# 11280, AB_2665517) (1:1000) was obtained from Signaling Antibody (SAB, Baltimore,
MD, USA); ant-FLAG antibody (Cat# SAB4200071, RRID:AB_10603396) was obtained from Sigma;
Alexa-Fluor-488-conjugated goat anti-rabbit IgG antibody and Alexa-Fluor-594-conjugated goat
anti-mouse IgG antibody were obtained from Life Technologies.
The following reagents were used in this study. Etoposide, 3-aminobenzamide (3-AB), PJ-34, ben-
zamide (BEN), ethidium bromide (EB), and human recombinant TNF-a were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Doxorubicin and camptothecin were obtained from KeyGEN Biotech
(Nanjing, China). Lipofectamine 3000 and Superfect Transfection Reagent were obtained from Invi-
trogen (Carlsbad, CA, USA) and Qiagen (Chatsworth, CA, USA), respectively. Protein A agarose was
obtained from the Millipore Corporation (Bedford, MA, USA). PhosSTOP Inhibitor Cocktail Tablets
and Complete Protease Inhibitor Cocktail Tablets were obtained from Roche Applied Science (Man-
nheim, Germany). Biotin-NAD+, NAD, human PARP enzyme, activated DNA, and PARP buffer were
purchased from Trevigen (Gaithersburg, MD, USA). GST Bind Resin was obtained from Novagen
(Madison, WI, USA). CCK-8 was obtained from Dojindo (Tokyo, Japan). Apoptosis Detection Kit was
obtained from BD Bioscience (San Jose, CA, USA).
Plasmids and transfection reagents
The constructs expressing wild-type LRP16 and LRP16 mutants have been described in our previous
report (Han et al., 2003, 2007; Wu et al., 2015; Yang et al., 2009). Wild-type PKR and its mutants
were cloned by PCR amplification into pcDNA3–FLAG. siRNA-resistant LRP16 was cloned by PCR
amplification into pcDNA3–FLAG. The dominant-negative mutant IkBm (IkBSR), as described previ-
ously (Wu et al., 2015), in which serines 32 and 36 were mutated to alanine, was inserted into the
pcDNA3–FLAG vector. The identities of all the constructs used in this study were verified by DNA
sequencing. Cells were transfected with the indicated plasmids using Superfect Reagent, as
described previously (Wu et al., 2011, 2015). For siRNA transfection, cells were plated at 30–60%
confluence in Opti-MEM serum-free medium and transfected with a specific siRNA duplex using Lip-
ofectamine RNAiMAX Transfection Reagent (Life Technologies, Paisley, UK), according to the manu-
facturer’s instructions for 48 hr. siRNAs were ordered as reverse phase (RP)-HPLC-purified duplexes





siPKR-3, 50-GCAGAUACAUCAGAGAUAA  30, and
siPKR-4,50-CCUGAGACCAGUGAUGAUU  30.
Apoptosis assay and cell proliferation assay (Edu staining)
Cells were plated and treated for 48 hr with the indicated reagents; 1  106 cells were washed with
cold PBS and resuspended in 100 ml of binding buffer. An apoptosis assay was performed with the
Annexin-V and propidium iodide using the protocol provided with the apoptosis detection kit (BD
Biosciences). Cells without Annexin V or propidium iodide were used to detect autofluorescence.
EdU staining was performed using the Click-iT EdU Alexa Fluor 488 Imaging Kit (Invitrogen), accord-
ing to the manufacturer’s protocol. EdU was added directly to the culture medium at a final
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concentration of 10 mM and incubated for 2 hr. The cells were fixed with 4% paraformaldehyde in
PBS for 15 min, and then permeabilized with 0.5% Triton X-100 for 20 min. Nuclei were counter-
stained with Hoechst 33342. Three biological replicates were prepared for each treatment and each
assay was performed in triplicate.
RNA isolation and quantitative real-time PCR (RT-qPCR) analysis
RNA from the cell lines was isolated with TRIzol Reagent and purified with the RNeasy Mini Kit
according to the manufacturer’s protocol (Qiagen). Aliquots of 1 mg of total RNA were reverse-tran-
scribed with the ThermoScript RT–PCR System (Invitrogen). RT–qPCR was performed according to
the instruction for SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) with the
ViiA 7 Real-Time PCR System (Applied Biosystems). Relative expression levels were calculated using
the 2 DDCT method. b-Actin was used as the housekeeping gene for normalization. The results for
these experiments were all reproducible and therefore only one of each experiment is presented.
Cell viability assay and clonogenic assay
Cells were seeded in 96-well plates overnight and treated with the indicated drugs. A CCK8 assay
was performed after incubation for 72 hr. Untreated cells were used to indicate 100% cell viability.
The absorbance (optical density, OD) was read at a wavelength of 450 nm on an enzyme-linked
immunosorbent assay (ELISA) plate reader. The cell viability rate was calculated as follows: (OD
treated/OD control)100%. The IC50 values were calculated with GraphPad Prism version 6.0
(GraphPad Software, La Jolla, CA, USA). The cells were trypsinized to generate a single-cell suspen-
sion, and seeded in six-well plates at 104 cells per well, and treated with or without the indicated
drugs. At 2–3 weeks after seeding, the colonies were stained with crystal violet as described previ-
ously (Li et al., 2013). Three biological replicates were prepared for each treatment and each assay
was performed in triplicate.
Immunofluorescence microscopy
The cells were immunostained as described previously (Wu et al., 2011, 2015). Briefly, the cells
were fixed in 4% paraformaldehyde (PFA) in PBS. After blocking and permeabilization with 0.3% Tri-
ton X-100% and 1% bovine serum albumin in PBS, the cells were probed with the indicated antibod-
ies. Alexa-Fluor-488- and Alexa-Fluor-594-labeled secondary antibodies were used to visualize the
immunofluorescent signals. Representative fluorescent images were acquired with a confocal laser
scanning microscope (FV1000, Olympus, Tokyo, Japan).
Western blot analysis and immunoprecipitation (IP) assays
Cells were washed with ice-cold PBS and lysed on ice for 30 min with RIPA lysis buffer supplemented
with protease inhibitors and PhosSTOP inhibitors. Protein concentrations were determined with the
Bradford Protein Assay Kit (Bio-Rad, Carlsbad, CA, USA) and a calibration standard curve created
with BSA. The samples were prepared for loading by adding 4  sample buffer (Invitrogen) and
heating the samples at 90˚C for 10 min. The total proteins were separated with SDS-PAGE. The pro-
teins in the gel were electrophoretically transferred to a PVDF membrane (Millipore), and then the
membrane was blocked in 5% milk or BSA with Tris-buffered saline/Triton X-100 buffer (100 mM
Tris-HCl [pH 7.4], 500 mM NaCl, 0.1% Triton X-100) (TBS-T 0.1%). The membranes were incubated
overnight at 4˚C with primary antibodies in 5% milk or BSA in 0.1% TBS-T. Horseradish peroxidase
(HRP)-conjugated secondary antibody was added and incubated for 1 hr at room temperature in
0.1% TBS-T, and the signals were visualized with an enhanced chemiluminescence system. Immuno-
precipitation (IP) experiments were performed, essentially as described previously (Wu et al., 2011,
2015; Yang et al., 2009). Briefly, for conventional IP experiments, cells were cultured to 70% conflu-
ence in 10 cm culture dishes. The cells were then either harvested without additional treatments or
after treatment with either IR or a specific genotoxic agent. The cells were then lysed with IP buffer
(50 mM Tris-HCl [pH 7.4], with 150 mM NaCl, 1 mM EDTA, and 1% Triton X-100) in the presence of
a protease inhibitor mixture. After a preclearing step with protein A/G-agarose beads (Upstate), the
protein lysate (1 mg) was immunoprecipitated with the agarose-immobilized antibody overnight at
4˚C. The blot was incubated with HRP-conjugated secondary antibody, and the signals were visual-
ized with an enhanced chemiluminescence system as described by the manufacturer. Similar results
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were obtained from two independent sets of experiments, and the result of one experiment is
presented.
Luciferase assay
Cells were seeded in 12-well plates. Experiments were set up as described previously (Wu et al.,
2011, 2015). Briefly, the cells were then transfected with a luciferase reporter plasmid containing 3
 kB–luc motifs and the indicated plasmids and/or siRNAs together with pRL-SV40. The total
amount of input DNA for each treatment was kept constant by supplementing it with pcDNA3.1. At
48 hr after transfection, the cells were either left untreated or treated with genotoxic stress. At the
time of harvest, the promoter activity was assessed with a dual-luciferase assay kit. Briefly, the feed-
ing medium was removed from the wells, and the cells were washed once with ice cold PBS and
lysed with 100 ml of ice-cold reporter lysis buffer. The cell lysate (10 ml) was then added to 50 ml of
luciferase substrate solution, after which 50 ml of Stop and Glow Buffer was added to visualize the
luciferase signal. The bioluminescence generated was measured with a luminometer (Berthold
Detection System, Pforzheim, Germany). The luminescence readings obtained were normalized to
the protein concentration of the corresponding cell lysate and presented as the fold difference rela-
tive to the control setup.
Recombinant protein expression and purification
For bacterial expression, IkBa cDNA (encoding aa 1–66) was cloned into pGEX-6p-1. The recombi-
nant fusion protein expressed by the pGEX-6p-1–LRP16 plasmid has been described in our previous
report (Wu et al., 2011, 2015). The procedure used to obtain the purified recombinant proteins
from Escherichia coli cells has been described previously (Wu et al., 2015). Escherichia coli BL21
cells were transformed with pGEX-6p-1, pGEX-6p-1-LRP16, or pGEX-6p-1-IkBa (aa 1–66) plasmid,
and at OD600 = 0.5–1.0, the cultures were induced with 100 mM IPTG for 10 hr at 20˚C. The crude
bacterial lysates were prepared by sonication (nine rounds of 20 s bursts on ice) in lysis buffer (40
mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 0.5% NP-40, and 10% [v/v] glycerol) in the pres-
ence of a protease inhibitor mixture. The GST-tagged recombinant proteins were then purified using
GST Bind Resin according to the manufacturer’s protocol.
GST pull-down assay
The GST-tagged proteins that were associated with the GST Bind Resin were incubated with various
proteins of interest. The GST pull-down assay was performed as described previously (Wu et al.,
2011, 2015). The total proteins that were associated with the beads were then analyzed by Western
blotting analysis using the appropriate antibodies. Each GST pull-down sample was analyzed three
times and reproducible results were obtained.
Mass spectrometry
The bead-associated FLAG-tagged proteins of interest were eluted by incubation with the 3  FLAG
Peptide antigen (Sigma). The eluted products were fractionated by an SDS-PAGE. The gel was then
subjected to silver staining, and the visible bands were excised and subjected to a mass-spectromet-
ric analysis.
Synthesis of polymers of ADP-Ribose (PAR) and PAR-binding assay
A 100 ml reaction mixture containing 3 ml of human PARP1 enzyme, 3 ml of 20 mM NAD or 250 mM
biotin–NAD, 10 ml of 10  activated DNA, and 5 ml of 20  PARP buffer was incubated at 25˚C for 1
hr. The reaction mixture was then used directly in a PAR-binding assay. The recombinant proteins
were incubated for 30 min at 32˚C in 40 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 0.5%
NP40, 10% (v/v) glycerol, biotin-labeled PAR and/or small molecules. The reaction mixtures were
applied to nitrocellulose and washed for 30 min with TBS-T containing 100 nM NaCl. After incuba-
tion with streptavidin–HRP, the bound biotin-labeled PAR was detected with a DAB Horseradish Per-
oxidase Color Development Kit. Each sample was detected three times. Each experiment was
performed three times, and reproducible results were obtained.
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Combination therapy and criteria for synergism
Cells were plated on 96-well plates and treated with various concentrations of each drug alone or in
combination, at a constant ratio. Following daily treatments for 4 days, the cells were assayed with
CellTiter 96 Aqueous One Solution Cell Proliferation Reagent (Promega, Madison, Wi, USA). The
absorbance values were used to determine the fraction of cells affected by each treatment and to
determine the combination indices (CIs) according to the Chou–Talalay method, using CompuSyn
software: CI <1 indicates synergism, CI = 1 indicates an additive effect, and CI >1 indicates an
antagonistic effect.
Gene expression microarray data analysis
The total RNA from colon cancer cells stably transfected with the control vector or LRP16-expressing
plasmid, and treated with or without etoposide (50 mM) for the indicated periods, was isolated and
purified with an RNeasy Kit (Qiagen, Hilden, Germany). The integrity of the RNA was assessed with
an Agilent BioAnalyzer 2100 (Agilent Technologies, Palo Alto, CA, USA). The samples were proc-
essed and hybridized to an Affymetrix GeneChip Human Transcriptome Array (HTA) 2.0, which con-
tains >6.0 million probes covering the exons of >65,000 coding and noncoding transcripts. The
gene expression microarray data were preprocessed and normalized with the Affymetrix Expression
Console software (V1.3.1) using the RMA sketch method. Several sources of gene sets were
selected, including gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG).
The sets included groups based on molecular function, cellular localization, biological processes,
and signaling pathways. The resulting lists were examined for their enrichment in terms of the GO
(biological process) and KEGG pathways. For the latter, pathways associated with diseases were fil-
tered out as reported (Li et al., 2013, 2014). The enrichment analysis was based on a hypergeomet-
ric test. p-Values were adjusted using Benjamini–Hochberg’s false discovery rate (FDR); only
FDRs <0.1 were considered. A correction for genes in overlapping clusters was applied.
Hematoxylin and eosin (H and E) staining and IHC analysis
Tumor tissues were fixed in 4% formaldehyde solution and processed routinely for paraffin embed-
ding. Sections were cut to a thickness of approximately 4 mm, placed on glass slides, and counter-
stained with H and E. For IHC, formalin-fixed paraffin-embedded tissue sections were dewaxed,
hydrated, heated for 2 min in a conventional pressure cooker, treated with 3% H2O2 for 20 min, and
then incubated with normal goat serum for 30 min. The sections were then incubated with antibod-
ies overnight. After washing, the sections were incubated with biotin-labeled secondary antibody for
20 min at 37˚C. The slides were then rinsed and incubated with streptavidin–biotin–peroxidase for
20 min. The color reaction was developed with 3,30-diaminobenzidine tetrahydrochloride. The IHC
specimens were independently assessed by two pathologists who were blinded to the origin of the
samples, including the clinicopathological data. The staining intensity and extent of the stained area
were graded according to the German semiquantitative scoring system: staining intensity of the
nucleus, cytoplasm, and/or membrane (no staining = 0; weak staining = 1; moderate staining = 2;
strong staining = 3); the extent of stained cells (0% = 0, 1%–24% = 1, 25%–49% = 2, 50%–74% = 3,
75%–100% = 4). The final immunoreactive score (0 to 12) was determined by multiplying the inten-
sity score by the extent of stained cells. Based on the QS, LRP16 expression was graded as low (0–1)
or high (2–3).
In vitro kinase assay
SW620 cells were transfected with either pooled LRP16 siRNAs or pooled PKR siRNAs for knock-
down. After 36 hr, the cells were lysed with IP buffer, and the kinase complex was prepared with an
anti-NEMO antibody. GST–IkBa (aa 1–66) was purified on a glutathione–agarose column and used
as the substrate. The reaction was performed with a mixture of the kinase complex, 0.5 mg of GST–
IkBa (aa 1–66), and 100 mM ATP in kinase buffer (25 mM Tris [pH 7.5], 10 mM MgCl2, 2 mM EGTA,
1 mM dithiothreitol, and 1 mM sodium orthovandate) + inhibitors (0.5 mM PMSF, 10 mM b-glycerol
phosphate (BGP), 300 mM sodium othovanadate, 1 mg/ml leupeptin, 1 mg/ml aprotinin, 10 mM
sodium fluoride, 10 mM p-nitrophenyl phosphate) at 30˚C for 30 min. The reactions were stopped
by the addition of 10 mM EDTA and stored at  20˚C until analysis by immunoblotting. The purified
IKK complex and GST–IkBa (aa 1–66) were analyzed by Western blotting with the appropriate
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antibodies. Each sample was detected two times. Each experiment was performed two times and
reproducible results were obtained.
Animal models
Tumor cell xenografts were generated as previously described (Li et al., 2013). Female 6–8 week-
old athymic nu/nu nude mice (RRID:IMSR_CRL:088) and BALB/c mice (RRID:IMSR_CRL:28) were pur-
chased from HFK Bioscience Co., Ltd (Beijing, China). Mice CT26 (ATCC Cat# CRL-2638, RRID:
CVCL_7256) was also obtained from ATCC (Manassas, VA) and the identities have been authenti-
cated by short tandem repeat DNA profiling. Cells described above were regularly tested for myco-
plasma contamination. All studies were approved by the Institutional Animal Care and Treatment
Committee of the Chinese PLA General Hospital.
Xenografts
Tumor cells (3  106) were injected subcutaneously into the lateral flanks of mice and allowed to
develop for 10–15 days. The tumor-bearing mice were randomized into groups and began treatment
when the average tumor volume reached 100–150 mm3. The mice with colon cancer xenografts
were treated with etoposide, MRS 2578, or their combination, given intraperitoneally, at the indi-
cated dose or with IR. For the combination treatment, both drugs were given concurrently. During
treatment, the tumor volume (V) was measured with a Vernier caliper 2–3 times per week and calcu-
lated with the formula V = (L  W2)/2, where L is the length and W is the width, as previously
described (Li et al., 2013). The volumes of the tumors treated with the vehicle control or the com-
pounds were compared, and the p values were determined with a two-tailed Student’s t test. At the
completion of the study, the mice were killed and necropsied, and the tumor tissues were removed
for further analysis.
Statistical analysis
All statistical analyses were performed with GraphPad Prism version 6.0 (GraphPad Software, La
Jolla, CA, USA). Two-tailed Student’s t test, two-way ANOVA, or one-way ANOVA with Dunnett’s
multiple comparisons test was used to compare the statistical differences between the relevant
groups. The synergistic effect in the animal study was analyzed with two-way ANOVA. A p
value < 0.05 was considered statistically significant. The half maximal inhibitory concentration (IC50)
values were calculated with GraphPad Prism version 6.0. For all in vivo experiments, we used the
GraphPad Prism software (ANOVA/Mann–Whitney test) to calculate the statistical significance of
differences.
Accession numbers
Microarray data were submitted to the NCBI Gene Expression Omnibus under accession number
GSE93625.
Acknowledgements
We thank prof. Chen Wang (Institute of Biochemistry and Cell Biology, Chinese Academy of Science,
Shanghai) for providing the kB–luc plasmid. We also thank prof. Yufang Shi (Institute of Translational
Medicine, Soochow University, Suzhou) and prof. Mingzhou Guo (Department of Gastroenterology
and Hepatology, Chinese PLA General Hospital) for critical reading and appraisal of the manuscript.
This work was supported by the grants from the National Natural Science Foundation of China (Nos.
81230061 to WDH, 81672797 to XLL, 81472612 to ZQW) and the Beijing Nova Program (No.
Z141107001814104 to XLL) and the Beijing Nova Program Interdisciplinary Studies Cooperative Proj-
ect (No. Z161100004916043 to XLL) and the National Key Research and Development Program of
China (Nos. 2016YFC1303501 and 2016YFC1303504 to WDH).
Li et al. eLife 2017;6:e27301. DOI: 10.7554/eLife.27301 29 of 34
Research article Cancer Biology Cell Biology
Additional information
Funding











National Key Research and









The funders had no role in study design, data collection and interpretation, or the decision to
submit the work for publication.
Author contributions
XLi, Conceptualization, Supervision, Funding acquisition, Project administration, Writing—review
and editing; ZW, Data curation, Funding acquisition, Investigation, Methodology, Writing—original
draft, Project administration; XA, Data curation, Formal analysis, Funding acquisition, Validation,
Investigation, Methodology, Project administration; QM, Resources, Data curation, Validation, Meth-
odology; MB, Data curation, Formal analysis, Investigation, Methodology; LH, Data curation, Meth-
odology; XLi, Investigation, Methodology, helped with screening the small molecules; TA,
Investigation, Methodology; WH, Conceptualization, Data curation, Supervision, helped with screen-




Human subjects: Human Subjects: The human patient study was approved by the Ethics Committee
of the Chinese PLA General Hospital (Beijing, China), and informed consent was obtained from all
patients (S2016-127-01). All samples were obtained in accordance with the Health Insurance Porta-
bility and Accountability Act (HIPAA).
Animal experimentation: Animal experimentation: This study was performed in strict accordance
with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health, and the protocol was approved by the Institutional Animal Care and Treatment
Committee of the Chinese PLA General Hospital (IACTC-CPGH-062). All surgery was performed
under sodium pentobarbital anesthesia, and every effort was made to minimize suffering.
Additional files
Major datasets
The following dataset was generated:






2017 Human colon cancer SW480 cells:
stably transfected with vector







Li et al. eLife 2017;6:e27301. DOI: 10.7554/eLife.27301 30 of 34
Research article Cancer Biology Cell Biology
without etoposide (accession no:
GSE93625)
The following previously published dataset was used:





















Bennett RL, Blalock WL, Abtahi DM, Pan Y, Moyer SA, May WS. 2006. RAX, the PKR activator, sensitizes cells to
inflammatory cytokines, serum withdrawal, chemotherapy, and viral infection. Blood 108:821–829. doi: 10.
1182/blood-2005-11-006817, PMID: 16861340
Benson AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J,
McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG. 2004. American Society of clinical oncology
recommendations on adjuvant chemotherapy for stage II Colon cancer. Journal of Clinical Oncology 22:3408–
3419. doi: 10.1200/JCO.2004.05.063, PMID: 15199089
Bernard D, Gosselin K, Monte D, Vercamer C, Bouali F, Pourtier A, Vandenbunder B, Abbadie C. 2004.
Involvement of rel/nuclear factor-kappaB transcription factors in keratinocyte senescence. Cancer Research 64:
472–481. doi: 10.1158/0008-5472.CAN-03-0005, PMID: 14744759
Bonnet MC, Weil R, Dam E, Hovanessian AG, Meurs EF. 2000. PKR stimulates NF-kappaB irrespective of its
kinase function by interacting with the IkappaB kinase complex. Molecular and Cellular Biology 20:4532–4542.
doi: 10.1128/MCB.20.13.4532-4542.2000, PMID: 10848580
Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. 2005.
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913–
917. doi: 10.1038/nature03443, PMID: 15829966
Cancer Genome Atlas Network. 2012. Comprehensive molecular characterization of human colon and rectal
cancer. Nature 487:330–337. doi: 10.1038/nature11252, PMID: 22810696
Chou TC. 2010. Drug combination studies and their synergy quantification using the Chou-Talalay method.
Cancer Research 70:440–446. doi: 10.1158/0008-5472.CAN-09-1947, PMID: 20068163
Cuddihy AR, Wong AH, Tam NW, Li S, Koromilas AE. 1999. The double-stranded RNA activated protein kinase
PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392
in vitro. Oncogene 18:2690–2702. doi: 10.1038/sj.onc.1202620, PMID: 10348343
D’Andrea AD. 2010. Susceptibility pathways in Fanconi’s anemia and breast cancer. The New England Journal of
Medicine 362:1909–1919. doi: 10.1056/NEJMra0809889, PMID: 20484397
Dar AC, Dever TE, Sicheri F. 2005. Higher-order substrate recognition of eIF2alpha by the RNA-dependent
protein kinase PKR. Cell 122:887–900. doi: 10.1016/j.cell.2005.06.044, PMID: 16179258
Davis AJ, Tannock JF. 2000. Repopulation of tumour cells between cycles of chemotherapy: a neglected factor.
The Lancet Oncology 1:86–93. doi: 10.1016/S1470-2045(00)00019-X, PMID: 11905673
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A,
Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. 2000.
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal Cancer.
Journal of Clinical Oncology 18:2938–2947. doi: 10.1200/JCO.2000.18.16.2938, PMID: 10944126
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